Agency of the United States Department of Health and Human Services
POPULARITY
Categories
357 episodes with fda
281 episodes with fda
183 episodes with fda
247 episodes with fda
229 episodes with fda
126 episodes with fda
183 episodes with fda
112 episodes with fda
147 episodes with fda
150 episodes with fda
273 episodes with fda
183 episodes with fda
178 episodes with fda
185 episodes with fda
53 episodes with fda
82 episodes with fda
75 episodes with fda
90 episodes with fda
65 episodes with fda
62 episodes with fda
135 episodes with fda
55 episodes with fda
70 episodes with fda
107 episodes with fda
107 episodes with fda
61 episodes with fda
68 episodes with fda
36 episodes with fda
96 episodes with fda
44 episodes with fda
50 episodes with fda
65 episodes with fda
44 episodes with fda
42 episodes with fda
105 episodes with fda
43 episodes with fda
64 episodes with fda
50 episodes with fda
47 episodes with fda
51 episodes with fda
61 episodes with fda
97 episodes with fda
78 episodes with fda
41 episodes with fda
38 episodes with fda
59 episodes with fda
64 episodes with fda
56 episodes with fda
55 episodes with fda
97 episodes with fda
73 episodes with fda
59 episodes with fda
49 episodes with fda
99 episodes with fda
Testosterone is the only natural hormone treated like a street drug—and the FDA just signaled that could change. In this episode, Amy Stuttle sits down with Rick Collins, Esq. (“Legal Muscle”)—one of the most well-known attorneys in the hormone, supplement, and peptide space—to break down the recent FDA expert panel on testosterone in men and what it could mean for patients, prescribers, and the industry. You'll hear them unpack: Why experts are pushing to de-schedule testosterone (currently Schedule III) The argument that low T is a health crisis, not “vanity” Why the panelists want the prostate cancer warning stripped and the outdated narrative retired The ongoing shift on cardiovascular risk, including the FDA's removal of the black box warning and discussion of the TRAVERSE trial The reality that most prescribing is effectively off-label under today's criteria—and why that may change A candid breakdown of the “research use only” peptide crackdown, why over-regulation fuels black markets, and where legitimate medical oversight fits in Follow Rick on Instagram at @RickCollinsESQ for updates as this story develops. Rick Collins Instagram Click Here Victory Men's Health Click Here Victory Men's Health YouTube For questions email podcast@amystuttle.com Disclaimer: The Women Want Strong Men Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional healthcare services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Scientists are expanding our understanding of MS at an unprecedented pace. This week, Dr. Leorah Freeman discusses why, as new discoveries and medications enter clinical practice, neurologists and MS specialists should ask themselves 3 important questions when considering a patient's treatment plan. Dr. Freeman is the Director of the Multiple Sclerosis and Neuroimmunology Center at Dell Medical School at the University of Texas at Austin, where she also leads the MS and Neuroimmunology fellowship program and the MS Imaging and Outcomes Research Laboratory. We'll also tell you about study results that reveal two distinct biologically-informed MS subtypes. We're explaining some of the confusing background to the FDA's decision not to approve a disease-modifying therapy that achieved positive results in its Phase 3 clinical trial. And did we really need a study to tell us that people living with MS fear experiencing a relapse or disease progression? Well, yes. We'll explain why. We're also reminding you to mail your insurance premium payments and other important documents earlier than you have in the past. And we're sharing details about the two clinical trials that received $4.1 million in funding as part of the International Progressive MS Alliance Experimental Medicine Trial Awards. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: 3 questions your neurologist should be asking themselves :22 Public Service Announcement: How the new rule about postmarks could affect your healthcare 1:16 FDA says it's not ready to approve Tolebrutinib 3:16 Study identifies two biologically-informed MS subtypes 6:29 Study results remind us that people with MS fear relapse and progression 10:09 The International Progressive MS Alliance invests $4.1 million in two clinical trials 14:04 Dr. Leorah Freeman discusses why neurologists need to ask themselves 3 important questions when considering a patient's treatment plan 17:18 Share this episode 33:16 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/436 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com The Multiple Sclerosis Insider https://themultiplesclerosisinsider.substack.com STUDY: Combined Magnetic Resonance Imaging and Serum Analysis Reveals Distinct Multiple Sclerosis Types https://academic.oup.com/brain/article/148/12/4578/8321558 STUDY: Fear of Disease Progression and Relapse in Multiple Sclerosis: A Systematic Scoping Review https://frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1680781/full JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 436 Guests: Dr. Leorah Freeman Privacy Policy
We love to hear from our listeners. Send us a message. This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what each editor has planned for 2026. From the RNA, cell, and gene therapy space to small molecule manufacturing, bioprocessing, drug discovery, and outsourcing, the editors weigh in on key industry trends, new developments, and policy surprises from their respective coverage areas. Topics include biotech funding dynamics, FDA leadership, China's growing role, favorite holiday movies, and much, much more. Special thanks to Tyler Menichiello and the Better Biopharma podcast for hosting this roundtable discussion. Happy New Year! Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Did Fentanyl Almost Kill a Cop? One Deputy's Story of Trauma, Survival, and a Mission to Help Others. Special Episode. For years, fentanyl has dominated headlines as a driving force behind America's overdose crisis. What's discussed far less often is how this drug impacts the first responders who encounter it in the line of duty. For Deputy Jeff Brown, a long-serving law enforcement officer, accidental fentanyl exposure didn't just spark a frightening moment, it caused permanent injuries, ongoing trauma, and a new mission focused on helping others. The Law Enforcement Talk Radio Show and Podcast on social media like their Facebook , Instagram , LinkedIn , Medium and other social media platforms. By any measure, Jeff Brown is a law enforcement hero. But one accidental fentanyl exposure nearly ended his life, and forever changed it. This special episode is streaming for free on the Law Enforcement Talk Radio Show and Podcast website, on Apple Podcasts, Spotify, YouTube, and most every major Podcast platform This is not just a story for the news-cycle. It's a story meant to be shared on Facebook, Instagram, YouTube, and across platforms like the Law Enforcement Talk Radio Show and Podcast website, Apple Podcasts and Spotify, because it speaks to the hidden cost of service, the reality of trauma, stress, PTSD, and the lasting injuries many heroes carry long after the call ends. Supporting articles about this and much more from Law Enforcement Talk Radio Show and Podcast in platforms like Medium , Blogspot and Linkedin . Accidental Fentanyl Exposure Almost Claimed His Life Jeff Brown had built a distinguished law enforcement career when one routine encounter with drug abusers turned into a life-threatening emergency. During the incident, Jeff and his backup deputies were accidentally exposed to fentanyl. The effects were immediate and terrifying. Had it not been for department-issued Narcan and the training the deputies received, Jeff believes he and others would not have survived. In a matter of minutes, deputies were forced to save each other's lives. Did Fentanyl Almost Kill a Cop? One Deputy's Story of Trauma, Survival, and a Mission to Help Others. Special Episode. Look for The Law Enforcement Talk Radio Show and Podcast on social media like their Facebook , Instagram , LinkedIn , Medium and other social media platforms. They lived, but not without consequence. For Jeff, the exposure caused permanent damage to his heart, altering his health and his future. What should have been just another shift became the defining moment of his life. The Aftermath: Injuries, Recovery, and a Broken System Surviving the incident was only the beginning. Jeff openly talks about: The physical recovery and lingering medical issues The emotional toll and ongoing stress Battles with Worker's Compensation The lack of understanding surrounding first responder injuries The rarely discussed crime problem in a tourist-driven resort area Like many first responders, Jeff learned that surviving the job does not guarantee support afterward. The system often struggles to recognize invisible injuries, especially when fear, misinformation, and stigma surround incidents involving fentanyl. Did Fentanyl Almost Kill a Cop? One Deputy's Story of Trauma, Survival, and a Mission to Help Others. Special Episode. Available for free on their website and streaming on Apple Podcasts, Spotify, Youtube and other podcast platforms. Fentanyl Misinformation and First Responder Trauma In 2016, the U.S. Drug Enforcement Administration (DEA) released advisories warning that simply touching or inhaling fentanyl could be fatal within minutes. Images of tiny, allegedly lethal doses circulated widely, reinforcing fear among first responders. At the time, the narrative felt plausible. Illicit fentanyl was flooding the streets, and officers had limited information. Later, medical experts, including the American College of Medical Toxicology and the American Academy of Clinical Toxicology clarified that incidental exposure leading to overdose is extremely unlikely. Other countries adjusted their guidance accordingly. Special Episode. The Law Enforcement Talk Radio Show and Podcast episode is available for free on their website , Apple Podcasts , Spotify and most major podcast platforms. But misinformation lingers, and it carries consequences. Officers who believe they've been exposed can experience panic attacks, hyperventilation, vertigo, and racing heart rates. These symptoms are real and distressing, yet often misinterpreted as fentanyl toxicity. In a culture where fear is seen as weakness, these events can go under-reported or misdiagnosed, potentially leading to delayed or inappropriate medical care. We stand by this critical point: Accidental fentanyl exposure can have drastic effects when combined with preexisting health conditions, particularly involving the heart. These incidents deserve serious, compassionate, and accurate medical evaluation. Did Fentanyl Almost Kill a Cop? One Deputy's Story of Trauma, Survival, and a Mission to Help Others. Special Episode. The special episode can be found on The Law Enforcement Talk Radio Show and Podcast website, on Apple podcasts, Spotify, Youtube and on LinkedIn, Facebook, Instagram, and across most podcast platforms where listeners will find authentic law enforcement stories. The FDA Warning: When Fentanyl Exposure Is Truly Deadly While incidental exposure myths persist among adults, there is one area where the danger is undisputed. The FDA warns that accidental exposure to fentanyl patches continues to be deadly to children. Fentanyl patches are prescribed for opioid-tolerant patients and release fentanyl through the skin over several days. Tragically, children have died after: Putting used or unused patches in their mouths Sticking patches onto their skin Even used patches can contain enough fentanyl to be fatal. The FDA urges caregivers to: Store patches securely Dispose of them properly Keep naloxone readily available If a child is suspected of exposure, call 911 immediately. Trauma, PTSD, and the Cost of Service Jeff's story highlights a truth many don't want to face: trauma doesn't end when the sirens stop. First responders routinely carry: Cumulative stress Psychological trauma PTSD Chronic health problems These issues affect not only their careers but their families, hobbies, and identities. For many even the simple joys of fishing and hunting, once outlets for peace, were impacted by his injuries and recovery. Did Fentanyl Almost Kill a Cop? One Deputy's Story of Trauma, Survival, and a Mission to Help Others. Special Episode. The full podcast episode is streaming now on their website, on Apple Podcasts, Spotify, Youtube and across Facebook, Instagram, and LinkedIn. Turning Pain Into Purpose: Hometown Heroes Alliance Instead of walking away, Jeff chose to give back. He now dedicates his time to Hometown Heroes Alliance, a nonprofit organization that supports wounded, injured, and disabled first responders, those who are often left financially and emotionally vulnerable after serving their communities. Hometown Heroes Alliance focuses on: Raising awareness for injured first responders Providing financial, physical, and emotional support Hosting benefit events, including concerts Producing brand-funded television and digital media to amplify impact From hurricane-stricken areas in Florida and Texas to less-publicized tragedies across the country, the organization helps heroes who lost homes, suffered disabling injuries, or sacrificed everything while protecting others. Did Fentanyl Almost Kill a Cop? One Deputy's Story of Trauma, Survival, and a Mission to Help Others. Special Episode. On the Law Enforcement Talk Radio Show and Podcast website on Apple Podcasts, Spotify, Youtube, Facebook, Instagram, LinkedIn, and most major podcast platforms. As long as there are heroes answering the call, there will be a need for compassion—and action. A Story That Needs to Be Heard Jeff Brown's journey is more than a headline. It's a reminder that behind every badge is a human being who absorbs trauma so others don't have to. This story belongs on every platform, Facebook, Instagram, YouTube, Apple, Spotify, and Podcast networks, because awareness saves lives, corrects misinformation, and honors those who continue to serve, even after the job nearly takes everything from them. He survived fentanyl exposure. He lives with the injuries. And he refuses to stop fighting for his fellow heroes. Find a wide variety of great podcasts online at The Podcast Zone Facebook Page , look for the one with the bright green logo. Be sure to check out our website . Be sure to follow us on X , Instagram , Facebook, Pinterest, Linkedin and other social media platforms for the latest episodes and news. Listeners can tune in on the Law Enforcement Talk Radio Show website, on Apple Podcasts, Spotify, YouTube, and most every major Podcast platform and follow updates on Facebook, Instagram, and other major News outlets. You can find the show on Facebook, Instagram, Pinterest, X (formerly Twitter), and LinkedIn, as well as read companion articles and updates on Medium, Blogspot, YouTube, and even IMDB. Background song Hurricane is used with permission from the band Dark Horse Flyer. You can contact John J. “Jay” Wiley by email at Jay@letradio.com , or learn more about him on their website . Stay connected with updates and future episodes by following the show on Facebook, Instagram, LinkedIn, their website and other Social Media Platforms. Interested in being a guest, sponsorship or advertising opportunities send an email to the host and producer of the show jay@letradio.com. Listen to this special episode on the Law Enforcement Talk Radio Show and Podcast website on Apple Podcasts, Spotify, Youtube, Facebook, Instagram, LinkedIn, and most major podcast platforms. Did Fentanyl Almost Kill a Cop? One Deputy's Story of Trauma, Survival, and a Mission to Help Others. Special Episode. Attributions NIH FDA.gov Hometown Heroes Alliance Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
John Gerardi and Jonathan Keller debut Right to Life Radio on the "50,000-watt mega blowtorch" KMJ with a fiery discussion about the growing tensions between pro-life organizations and the Trump administration. They break down the FDA's slow-rolling review of the abortion pill, the political risks of inaction, and the backlash from Susan B. Anthony Pro-Life America, Lila Rose, and other key advocates. The hosts also analyze the 2022 midterms, why Trump's team wants to avoid the abortion conversation, and the controversy surrounding Josh and Erin Hawley's new "Love Life" initiative.
Karen takes a look at GLP-1 receptor agonists, best known for weight loss and diabetes. She explores the rapidly expanding list of conditions these medications may help treat. From emerging and sometimes conflicting research on Parkinson's and Alzheimer's disease to FDA-approved benefits for cardiovascular health, kidney disease, and fatty liver disease, Karen breaks down what the science currently shows and where caution is still needed.Visit our website itchyandbitchy.com to read blog posts on the many topics we have covered on the show.
On this episode of Vitality Radio, Jared is joined by his wife Jen to explore how folic acid, a synthetic B vitamin, is affecting our health - and the role of genetics in it all. What began as a simple dietary change unexpectedly revealed how folic acid in fortified foods, different forms of B vitamins, and individual genetics can significantly influence mood, energy, and mental clarity. Jared and Jen share their personal experience removing folic acid, adjusting B12 forms, and learning why some people thrive on methylated B vitamins while others feel worse. You'll learn the key differences between folic acid and folate, why more supplementation isn't always better, how B12 forms like methylcobalamin, hydroxocobalamin, and adenosylcobalamin behave differently in the body, and why B6, B12, and folate must work together as a team. This episode provides a practical framework for understanding why “doing everything right” doesn't always lead to optimal results—and how thoughtful experimentation, label reading, and food quality make a meaningful difference.B Vitamin Products DiscussedAdditional Information:Episode #601 Blog Post#505: Emotional Vitality: Jen's Story Part 5 - The Impact of Diet on Mental Health and Physical PainCheck out all five“Jen's Story” Episodes!Visit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
In this week's Fraud Friday, Laci revisits Episode 152 and chats with journalist and podcast host Sam Sanders (The Sam Sanders Show) about Bishop Lamor Whitehead, who initially gained sympathy after being robbed during a livestreamed sermon. Now, his integrity is under scrutiny as details of his past crimes have emerged. Plus, the viral TikTok Pink Sauce is called out for not being FDA approved. Stay schemin'! (Originally released 08/22/2022) CONgregation, catch Laci's TV Show, Scam Goddess, now on Freeform and Hulu!Keep the scams coming and snitch on your friends by emailing us at ScamGoddessPod@gmail.com. Follow on Instagram:Scam Goddess Pod: @scamgoddesspodLaci Mosley: @divalaciSam Sanders: @samsanders Research by Kaelyn Brandt SOURCES:https://www.thecity.nyc/brooklyn/2022/7/29/23284458/brooklyn-pastor-lamor-whitehead-pleads-for-sympathyhttps://www.nytimes.com/2022/08/04/nyregion/lamor-whitehead-bishop-robbed.htmlhttps://www.curbed.com/2022/07/bishop-lamor-whitehead-real-estate-holdings-default.htmlhttps://bestlifeonline.com/news-robbed-pastor-whitehead-life-details/https://www.tasteofhome.com/article/tiktok-viral-pink-sauce/https://www.eater.com/23284219/pink-sauce-tiktok-color-expert-reactions Subscribe to SiriusXM Podcasts+ to listen to new episodes of Scam Goddess ad-free and a whole week early. Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This episode is a powerful conversation pulled from Fertility Rally Live in November 2025,, where we gathered an incredible panel to talk candidly about surrogacy — from every angle.Moderated by Jessie Jaskulsky of Surrogacy Simplified, the panel includes surrogacy mama Sarrah Strimmel Bentley, experienced surrogate Emily Westerfield, and surrogacy mama Alexandra French of The Surrogacy Foundation for an honest, nuanced discussion about what surrogacy really looks like — emotionally, logistically, ethically, and financially. Covered in the chat: How people arrive at surrogacy (and how complicated that decision can be)The relationship between intended parents and gestational carriersCommon misconceptions and hard truthsWhat surprised them most along the wayWhat they wish they'd known before startingWhether you're just beginning to explore surrogacy from an Intended Parent or Surrogate POV, deep in the process, supporting someone who is, or simply want to better understand this path to parenthood, this conversation is thoughtful, real, and incredibly informative. As always — no sugarcoating, no toxic positivity, just real stories from people who've lived it. EPISODE SPONSORS: THE WORK OF ART BOOK SERIESAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe latest book in the Work of ART series, “You Are a Work of ART," is for every kiddo born through ART -- and the people who love them.Order "Work of ART," "Beautiful Bird" and "You Are a Work of ART," now at https://www.infertileafgroup.com/booksFERTILITY RALLYIG: @fertilityrallywww.fertilityrally.comNo one should go through infertility alone. Join the Worst Club with the Best Members at fertilityrally.com. We offer 5 to 6 support groups per week, three private Facebook groups, tons of curated IRL and virtual events, and an entire community of more than 500 women available to support you, no matter where you are in your journey.Join today at link in bio on IG @fertilityrally or at www.fertilityrally.com/membershipPHERDALIG: @pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Go to PherDal.com today and use code INFERTILEAF for $10 off.BELIIG: @belibabywww.belibaby.com Are you thinking about growing your family? Whether you're just starting to plan or are actively trying to conceive, preconception health is key. Beli has vitamins to help both women and men optimize their health before pregnancy. With essential nutrients like Folate, Iodine, and Zinc, Beli ensures your body is ready for this exciting next step. Give yourself and your future baby the best foundation for a healthy start.Visit Belibaby.com today and use code IAF15 for 15% off your first order. Support this podcast at — https://redcircle.com/infertile-af-infertility-and-modern-family-building-through-art/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
In mid-December 2025, the FDA approved an at home devicethat aims to treat depression by sending electric current into a part of the brain (the prefrontal cortex) known to regulate mood. This has been available in the UK since 2019 but it is new to the US. The manufacturer has stated that over 55,000 patients have used the device across Europe, the UK, Switzerland, and Hong Kong. How does this work? Is there data to support this new therapy? In this episode, we will summarize three consecutive years of data (2023, 2024,2025) to answer that question. Listen in for details. 1. Sci Amer: https://www.scientificamerican.com/article/u-s-approves-first-device-to-treat-depression-with-brain-stimulation-at-home/2. August 12, 2023: Burkhardt, Gerrit et al.Transcranial direct current stimulation as an additional treatment to selectiveserotonin reuptake inhibitors in adults with major depressive disorder inGermany (DepressionDC): a triple-blind, randomised, sham-controlled,multicentre trial The Lancet, Volume 402, Issue 10401, 545 – 5543. October 21, 2024: Woodham, R.D., Selvaraj, S.,Lajmi, N. et al. Home-based transcranial direct current stimulation treatmentfor major depressive disorder: a fully remote phase 2 randomizedsham-controlled trial. Nat Med 31, 87–95 (2025). https://doi.org/10.1038/s41591-024-4. December 15, 2025: Moshfeghinia R, Bordbar S,Roointanpour Y, Arab Bafrani M, Shalbafan M. Efficacy and safety of home-basedtranscranial direct current stimulation (tDCS) on patients with depressivedisorders: a systematic review and meta-analysis of randomized clinical trials.Sci Rep. 2025 Dec 15;15(1):43850. doi: 10.1038/s41598-025-28648-5. PMID:41398008; PMCID: PMC12705823.
Dr. DebWhat if I told you that the stomach acid medication you’re taking for heartburn is actually causing the problem it’s supposed to solve that your doctor learned virtually nothing about nutrition, despite spending 8 years in medical school. That the very system claiming to heal you was deliberately designed over a hundred years ago by an oil tycoon, John D. Rockefeller, to create lifelong customers, not healthy people. Last week a patient spent thousands of dollars on tests and treatments for acid reflux, only to discover she needed more stomach acid, not less. The medication keeping her sick was designed to do exactly that. Today we’re exposing the greatest medical deception in modern history, how a petroleum empire systematically destroyed natural healing wisdom turned medicine into a profit machine. And why the treatments, keeping millions sick were engineered that way from the beginning. This isn’t about conspiracy theories. This is a documented history that explains why you feel so lost about your own body’s needs welcome back to let’s talk wellness. Now the show where we uncover the root causes of chronic illness, explore cutting edge regenerative medicine, and empower you with the tools to heal. I’m Dr. Deb. And today we’re diving into how the Rockefeller Medical Empire systematically destroyed natural healing wisdom and replaced it with profit driven systems that keeps you dependent on treatments instead of achieving true health. If you or someone you love has been running to the doctor for every minor ailment, taking acid blockers that seem to make digestive problems worse, or feeling confused about basic body functions that our ancestors understood instinctively. This episode is for you. So, as usual, grab a cup of coffee, tea, or whatever helps you unwind. Settle in and let’s get started on your journey to reclaiming your health sovereignty all right. So here we are talking about the Rockefeller Medical Revolution. Now, what if your symptoms aren’t true diagnosis, but rather the predictable result of a medical system designed over a hundred years ago to create lifelong customers instead of healthy people. Now I learned this when I was in naturopathic school over 20 years ago. And it hasn’t been talked about a lot until recently. Recently. People are exposing the truth about what actually happened in our medical system. And today I want to take you back to the early 19 hundreds to understand how we lost the basic health wisdom that sustained humanity for thousands of years. Yes, I said that thousands of years. This isn’t conspiracy theory. This is documented history. That explains why you feel so lost when it comes to your own body’s needs. You know by the turn of the 20th century. According to meridian health Clinic’s documentation. Rockefeller controlled 90% of all petroleum refineries in America and through ownership of the Standard Oil Corporation. But Rockefeller saw an opportunity that went far beyond oil. He recognized that petrochemicals could be the foundation for a completely new medical system. And here’s what most people don’t know. Natural and herbal medicines were very popular in America during the early 19 hundreds. According to Staywell, Copper’s historical analysis, almost one half of medical colleges and doctors in America were practicing holistic medicine, using extensive knowledge from Europe and native American traditions. People understood that food was medicine, that the body had natural healing mechanisms, and that supporting these mechanisms was the key to health. But there was a problem with the Rockefeller’s business plan. Natural medicines couldn’t be patented. They couldn’t make a lot of money off of them, because they couldn’t hold a patent. Petrochemicals, however, could be patented, could be owned, and could be sold for high profits. So Rockefeller and Andrew Carnegie devised a systematic plan to eliminate natural medicine and replace it with petrochemical based pharmaceuticals and according to E. Richard Brown’s comprehensive academic documentation in Rockefeller, medicine men. Medicine, and capitalism in America. They employed the services of Abraham Flexner, who proceeded to visit and assess every single medical school in us and in Canada. Within a very short time of this development, medical schools all around the us began to collapse or consolidate. The numbers are staggering. By 1910 30 schools had merged, and 21 had closed their doors of the 166 medical colleges operating in 19 0, 4, a hundred 33 had survived by 1910 and a hundred 4 by 1915, 15 years later, only 76 schools of medicine existed in the Us. And they all followed the same curriculum. This wasn’t just about changing medical education. According to Staywell’s copper historical analysis. Rockefeller and Carnegie influenced insurance companies to stop covering holistic treatments. Medical professionals were trained in the new pharmaceutical model and natural solutions became outdated or forgotten. Not only that alternative healthcare practitioners who wanted to stay practicing in alternative medicine were imprisoned for doing so as documented by the potency number 710. The goal was clear, create a system where scientists would study how plants cure disease, identify which chemicals in the plants were effective and then recreate a similar but not identical chemical in the laboratory that would be patented. E. Richard Brown’s documents. The story of how a powerful professional elite gained virtual homogeny in the western theater of healing by effectively taking control of the ethos and practice of Western medicine. The result, according to the healthcare spending data, the United States now spends 17.6% of its Gdp on health care 4.9 trillion dollars in 2023, or 14,570 per person nearly twice as much as the average Oecd country. But it doesn’t focus on cure. But on symptoms, and thus creating recurring clients. This systematic destruction of natural medicine explains why today’s healthcare providers often seem baffled by simple questions about nutrition why they immediately reach for a prescription medication for minor ailments, and why so many people feel disconnected from their own body’s wisdom. We’ve been trained over 4 generations to believe that our bodies are broken, and that symptoms are diseases rather than messages, and that external interventions are always superior to supporting natural healing processes. But here’s what they couldn’t eliminate your body’s innate wisdom. Your digestive system still functions the same way it did a hundred years ago. Your immune system still follows the same patterns. The principles of nutrition, movement and stress management haven’t changed. We’ve just forgotten how to listen and respond. We’re gonna take a small break here and hear from our sponsor. When we come back. We’re gonna talk about the acid reflux deception, and why your cure is making you sicker, so don’t go away all right, welcome back. So I want to give you a perfect example of how Rockefeller medicine has turned natural body wisdom upside down, the treatment of acid, reflux, and heartburn. Every single day in my practice I see patients who’ve been taking acid blocker medications, proton pump inhibitors like prilosec nexium or prevacid for years, not for weeks, years, and sometimes even decades. They come to me because their digestive problems are getting worse, not better. They have bloating and gas and nutrition deficiencies. And we’re seeing many more increased food sensitivities. And here’s what’s happening in the Us. Most people often attribute their digestive problems to too much stomach acid. And they use medications to suppress the stomach acid, but, in fact symptoms of chronic acid, reflux, heartburn, or gerd, can also be caused by too little stomach acid, a condition called hyper. Sorry hypochlorhydria normal stomach acid has a Ph level of one to 2, which is highly acidic. Hydrochloric acid plays an important role in your digestion and your immunity. It helps to break down proteins and absorb essential nutrients, and it helps control viruses and bacteria that might otherwise infect your stomach. But here’s the crucial part that most people don’t understand, and, according to Cleveland clinic, your stomach secretes lower amounts of hydrochloric acid. As you age. Hypochlorhydria is more common in people over the age of 40, and even more common over the age of 65. Webmd states that the stomach acid can produce less acid as a result of aging and being 65 or older is a risk factor for developing hypochlorhydria. We’ve been treating this in my practice for a long time. It’s 1 of the main foundations that we learn as naturopathic practitioners and as naturopathic doctors, and there are times where people need these medications, but they were designed to be used short term not long term in a 2,013 review published in Medical News today, they found that hypochlorhydria is the main change in the stomach acid of older adults. and when you have hypochlorydria, poor digestion from the lack of stomach, acid can create gas bubbles that rise into your esophagus or throat, carrying stomach acid with them. You experience heartburn and assume that you have too much acid. So you take acid blockers which makes the underlying problem worse. Now, here’s something that will shock you. PPI’s protein pump inhibitors were originally studied and approved by the FDA for short-term use only according to research published in us pharmacists, most cases of peptic ulcers resolve in 6 to 8 weeks with PPI therapy, which is what these medications were created for. Originally the American family physician reports that for erosive esophagitis. Omeprazole is indicated for short term 4 to 8 weeks. That’s it. Treatment and healing and done if needed. An additional 4 to 8 weeks of therapy may be considered and the University of Minnesota College of Pharmacy, States. Guidelines recommended a treatment duration of 8 weeks with standard once a day dosing for a PPI for Gerd. The Canadian family physician, published guidelines where a team of healthcare professionals recommended prescribing Ppis in adults who suffer from heartburn and who have completed a minimum treatment of 4 weeks in which symptoms were relieved. Yet people are taking these medications for years, even decades far beyond their intended duration of use and a study published in Pmc. Found that the threshold for defining long-term PPI use varied from 2 weeks to 7 years of PPI use. But the most common definition was greater than one year or 6 months, according to the research in clinical context, use of Ppis for more than 8 weeks could be reasonably defined as long-term use. Now let’s talk about what these acid blocker medications are actually doing to your body when used. Long term. The research on long term PPI use is absolutely alarming. According to the comprehensive review published in pubmed central Pmc. Long-term use of ppis have been associated with serious adverse effects, including kidney disease, cardiovascular disease fractures because you’re not absorbing your nutrients, and you’re being depleted. Infections, including C. Diff pneumonia, micronutrient deficiencies and hypomagnesium a low level of magnesium anemia, vitamin, b, deficiency, hypocalcemia, low calcium, low potassium. and even cancers, including gastric cancer, pancreatic cancer, colorectal cancer. And hepatic cancer and we are seeing all of these cancers on a rise, and we are now linking them back to some of these medications. Mayo clinic proceedings published research showing that recent studies regarding long-term use of PPI medication have noted potential adverse effects, including risks of fracture, pneumonia, C diff, which is a diarrhea. It’s a bacteria, low magnesium, low b 12 chronic kidney disease and even dementia. And a 2024 study published in nature communications, analyzing over 2 million participants from 5 cohorts found that PPI use correlated with increased risk of 15 leading global diseases, such as ischemic heart disease. Diabetes, respiratory infections, chronic kidney disease. And these associations showed dose response relationships and consistency across different PPI types. Now think about this. You take a medication for heartburn that was designed for 4 to 8 weeks of use, and when used long term, it actually increases your risk of life, threatening infections, kidney disease, and dementia. This is the predictable result of suppressing a natural body function that exists for important reasons. Hci plays a key role in many physiological processes. It triggers, intestinal hormones, prepares folate and B 12 for absorption, and it’s essential for absorption of minerals, including calcium, magnesium, potassium, zinc, and iron. And when you block acid production, you create a cascade of nutritional deficiencies and immune system problems that often manifest as seemingly unrelated health issues. So what’s the natural approach? Instead of suppressing stomach acid, we need to support healthy acid production and address the root cause of reflux healthcare. Providers may prescribe hcl supplements like betaine, hydrochloric acid. Bhcl is what it’s called. Sometimes it’s called betaine it’s often combined with enzymes like pepsin or amylase or lipase, and it’s used to treat hydrochloric acid deficiency, hypochlorhydria. These supplements can help your digestion and sometimes help your stomach acid gradually return back to normal levels where you may not need to use them all the time. Simple strategies include consuming protein at the beginning of the meal to stimulate Hcl production, consume fluids separately at least 30 min away from meals, if you can, and address the underlying cause like chronic stress and H. Pylori infections. This is such a sore subject for me. So many people walk around with an H. Pylori infection. It’s a bacterial infection in the stomach that can cause stomach ulcers, causes a lot of stomach pain and burning. and nobody is treating the infection. It’s a bacterial infection. We don’t treat this anymore with antibiotics or antimicrobials. We treat it with Ppis. But, Ppis don’t fix the problem. You have to get rid of the bacteria once the bacteria is gone, the gut lining can heal. Now it is a common bacteria. It can reoccur quite frequently. It’s highly contagious, so you can pick it up from other people, and it may need multiple courses of treatment over a person’s lifetime. But you’re actually treating the problem. You’re getting rid of the bacteria that’s creating the issue instead of suppressing the acid. That’s not fixing the bacteria which then leads to a whole host of other problems that we just talked about. There are natural approaches to increase stomach acid, including addressing zinc deficiency. And since the stomach uses zinc to produce Hcl. Taking probiotics to help support healthy gut bacteria and using digestive bitters before meals can be really helpful. This is exactly what I mean about reclaiming the body’s wisdom. Instead of suppressing natural functions, we support them instead of creating drug dependency, we restore normal physiology. Instead of treating symptoms indefinitely, we address the root cause and help the body heal itself. In many cultures. Bitters is a common thing to use before or after a meal. But yet in the American culture we don’t do that anymore. We’ve not passed on that tradition. So very few people understand how to use bitters, or what bitters are, or why they’re important. And these basic things that can be used in your food and cooking and taking could replace thousands of dollars of medication that you don’t really need. That can create many more problems along the way. Now, why does your doctor know nothing about nutrition. Well, I want to address something that might shock you all. The reason your doctor seems baffled when you ask about nutrition isn’t because they’re not intelligent. It’s because they literally never learned this in medical school statistics on nutritional education in medical schools are staggering and help explain why we have such a health literacy crisis in America. According to recent research published in multiple academic journals, only 27% of Us. Medical schools actually offer students. The recommended 25 h of nutritional training across 4 years of medical school. That means 73% of the medical schools don’t even meet the minimum standards set in 1985. But wait, it gets worse. A 2021 survey of medical schools in the Us. And the Uk. Found that most students receive an average of only 11 h of nutritional training throughout their entire medical program. and another recent study showed that in 2023 a survey of more than a thousand Us. Medical students. About 58% of these respondents said they received no formal nutritional education while in medical school. For 4 years those who did averaged only 3 h. I’m going to say this again because it’s it’s huge 3 h of nutritional education per year. So let me put this in perspective during 4 years of medical school most students spend fewer than 20 h on nutrition that’s completely disproportionate to its health benefits for patients to compare. They’ll spend hundreds of hours learning about pharmaceutical interventions, but virtually no time learning how food affects health and disease. Now, could this be? Why, when we talk about nutrition to lower cholesterol levels or control your diabetes, they blow you off, and they don’t answer you. It’s because they don’t understand. But yet what they’ll say is, people won’t change their diet. That’s why you have to take medication. That’s not true. I will tell you. I work with people every single day who are willing to change their diet. They’re just confused by all the information that’s out there today about nutrition. And what diet is the right diet to follow? Do I do, Paleo? Do I do? Aip? Do I do carnivore? Do I do, Keto? Do I do? Low carb? There’s so many diets out there today? It’s confusing people. So I digress. But let’s go back. So here’s the kicker. The limited time medical students do spend on nutrition office often focuses on nutrients think proteins and carbohydrates rather than training in topics such as motivational interviewing or meal planning, and as one Stanford researcher noted, we physicians often sound like chemists rather than counselors who can speak with patients about diet. Isn’t that true? We can speak super high level up here, but we can’t talk basics about nutrition. And this explains why only 14% of the physicians believe they were adequately trained in nutritional counseling. Once they entered practice and without foundational concepts of nutrition in undergrad work. Graduate medical education unsurprisingly falls short of meeting patients, needs for nutritional guidance in clinical practice, and meanwhile diet, sensitive chronic diseases continue to escalate. Although they are largely preventable and treatable by nutritional therapies and dietary. Lifestyle changes. Now think about this. Diet. Related diseases are the number one cause of death in the Us. The number one cause. Yet many doctors receive little to no nutritional education in medical school, and according to current health statistics from 2017 to march of 2020. Obesity prevalence was 19.7% among us children and adolescents affecting approximately 14.7 million young people. About 352,000 Americans, under the age of 20, have been diagnosed with diabetes. Let me say this again, because these numbers are astounding to me. 352,000 Americans, under the age of 20, have been diagnosed with diabetes with 5,300 youth diagnosed with type, 2 diabetes annually. Yet the very professionals we turn to for health. Guidance were never taught how food affects these conditions and what drug has come to the rescue Glp. One S. Ozempic wegovy. They’re great for weight loss. They’re great for treating diabetes. But why are they here? Well, these numbers are. Why, they’re here. This is staggering to put 352,000 Americans under the age of 20 on a glp, one that they’re going to be on for the rest of their lives at a minimum of $1,200 per month. All we have to do is do the math, you guys, and we can see exactly what’s happening to our country, and who is getting rich, and who is getting the short end of the stick. You’ve become a moneymaker to the pharmaceutical industry because nobody has taught you how to eat properly, how to live, how to have a healthy lifestyle, and how to prevent disease, or how to actually reverse type 2 diabetes, because it’s reversible in many cases, especially young people. And we do none of that. All we do is prescribe medications. Metformin. Glp, one for the rest of your life from 20 years old to 75, or 80, you’re going to be taking medications that are making the pharmaceutical companies more wealth and creating a disease on top of a disease on top of a disease. These deficiencies in nutritional education happen at all levels of medical training, and there’s been little improvement, despite decades of calls for reform. In 1985, the National Academy of Sciences report that they recommended at least 25 h of nutritional education in medical school. But a 2015 study showed only 29% of medical schools met this goal, and a 2023 study suggests the problem has become even worse. Only 7.8% of medical students reported 20 or more hours of nutritional education across all 4 years of medical school. This systemic lack of nutrition, nutritional education has been attributed to several factors a dearth of qualified instructors for nutritional courses, since most physicians do not understand nutrition well enough to teach it competition for curriculum time, with schools focusing on pharmaceutical interventions rather than lifestyle medicine and a lack of external incentives that support schools, teaching nutrition. And ironically, many medical schools are part of universities that have nutrition departments with Phd. Trained professors who could fill this gap by teaching nutrition in medical schools but those classes are often taught by physicians who may not have adequate nutritional training themselves. This explains so much about what I see in my practice. Patients come to me confused and frustrated because their primary care doctors can’t answer basic questions about how food affects their health conditions. And these doctors aren’t incompetent. They simply were never taught this information. And the result is that these physicians graduate, knowing how to prescribe medications for diabetes, but not how dietary changes can prevent or reverse it. They can treat high blood pressure with pharmaceuticals, but they may not know that specific nutritional approaches can be equally or more effective. This isn’t the doctor’s fault. It’s the predictable result of medical education systems that was deliberately designed to focus on patentable treatments rather than natural healing approaches. And remember this traces back to the Rockefeller influence on medical education. You can’t patent an apple or a vegetable. But you can patent a drug now. Why can’t we trust most medical studies? Well this just gets even better. I need to address something that’s crucial for you to understand as you navigate health information. Why so much of the medical research you hear about in the news is biased, and why peer Review isn’t the gold standard of truth you’ve been told it is. The corruption in medical research by pharmaceutical companies is not a conspiracy theory. It’s well documented scientific fact, according to research, published in frontiers, in research, metrics and analytics. When pharmaceutical and other companies sponsor research, there is a bias. A systematic tendency towards results serving their interests. But the bias is not seen in the formal factors routinely associated with low quality science. A Cochrane Review analyzed 75 studies of the association between industry, funding, and trial results, and these authors concluded that trials funded by a drug or device company were more likely to have positive conclusions and statistically significant results, and that this association could not be explained by differences in risk of bias between industry and non-industry funded trials. So think about that. According to the Cochrane collaboration, industry funding itself should be considered a standard risk of bias, a factor in clinical trials. Studies published in science and engineering ethics show that industry supported research is much more likely to yield positive outcomes than research with any other sponsorship. And here’s how the bias gets introduced through choice of compartor agents, multiple publications of positive trials and non-publication of negative trials reinterpreting data submitted to regulatory agencies, discordance between results and conclusions, conflict of interest leading to more positive conclusions, ghostwriting and the use of seating trials. Research, published in the American Journal of Medicine. Found that a result favorable to drug study was reported by all industry, supported studies compared with two-thirds of studies, not industry, supported all industry, supported studies showed favorable results. That’s not science that’s marketing, masquerading as research. And according to research, published in sciencedirect the peer review system which we’re told ensures quality. Science has a major limitation. It has proved to be unable to deal with conflicts of interest, especially in big science contexts where prestigious scientists may have similar biases and conflicts of interest are widely shared among peer reviewers. Even government funded research can have conflicts of interest. Research published in pubmed States that there are significant benefits to authors and investigators in participating in government funded research and to journals in publishing it, which creates potentially biased information that are rarely acknowledged. And, according to research, published in frontiers in research, metrics, and analytics, the pharmaceutical industry has essentially co-opted medical knowledge systems for their particular interests. Using its very substantial resources. Pharmaceutical companies take their own research and smoothly integrate it into medical science. Taking advantage of the legitimacy of medical institutions. And this corruption means that much of what passes for medical science is actually influenced by commercial interests rather than pursuant of truth. Research published in Pmc. Shows that industry funding affects the results of clinical trials in predictable directions, serving the interests of the funders rather than the patients. So where can we get this reliable, unbiased Health information, because this is critically important, because your health decisions should be based on the best available evidence, not marketing disguised as science. And so here are some sources that I recommend for trustworthy health and nutritional information. They’re independent academic sources. According to Harvard Chan School of public health their nutritional, sourced, implicitly states their content is free from industry, influence, or support. The Linus Pauling Institute, Micronutrient Information Center at Oregon State University, which, according to the Glendale Community college Research Guide provides scientifically accurate information about vitamins, minerals, and other dietary factors. This Institute has been around for decades. I’ve used it a lot. I’ve gotten a lot of great information from them. Very, very trustworthy. According to the Glendale Community College of Nutrition Resource guide Tufts, University of Human Nutritional Research Center on aging is one of 6 human nutrition research centers supported by the United States Department of Agriculture, the Usda. Their peer reviewed journals with strong editorial independence though you must still check funding resources. And how do you evaluate this information? Online? Well, according to medlineplus and various health literacy guides when evaluating health information medical schools and large professional or nonprofit organizations are generally reliable sources, but remember, it is tainted by the Rockefeller method. So, for example, the American College of cardiology. Excuse me. Professional organization and the American Heart Institute a nonprofit are both reliable sources. Sorry about that of information on heart health and watch out for ads designed to look like neutral health information. If the site is funded by ads they should be clearly marked as advertisements. Excuse me, I guess I’m talking just a little too much now. So when the fear of medicine becomes deadly. Now, I want to address something critically important that often gets lost in conversations about health, sovereignty, and questioning the medical establishment. And while I’ve spent most of this episode explaining how the Rockefeller medical system has created dependency and suppressed natural healing wisdom. There’s a dangerous pendulum swing happening that I see in my practice. People becoming so fearful of pharmaceutical interventions that they refuse lifesaving treatments when they’re genuinely needed. This is where balance and clinical judgment become absolutely essential. Yes, we need to reclaim our basic health literacy and reduce our dependency on unnecessary medical interventions. But there are serious bacterial infections that require immediate antibiotic treatment, and the consequences of avoiding treatment can be devastating or even fatal. So let me share some examples from research that illustrate when antibiotic fear becomes dangerous. Let’s talk about Lyme disease, and when natural approaches might not be enough. The International Lyme Disease Association ilads has conducted extensive research on chronic lyme disease, and their findings are sobering. Ileds defines chronic lyme disease as a multi-system illness that results from an active and ongoing infection of pathogenic members of the Borrelia Brdorferi complex. And, according to ilads research published in their treatment guidelines, the consequences of untreated persistent lyme infection far outweigh the potential consequences of long-term antibiotic therapy in well-designed trials of antibiotic retreatment in patients with severe fatigue, 64% in the treatment arm obtained clinically significant and sustained benefit from additional antibiotic therapy. Ilas emphasizes that cases of chronic borrelia require individualized treatment plans, and when necessary antibiotic therapy should be extended their research demonstrates that 20 days of prophylactic antibiotic treatment may be highly effective for preventing the onset of lyme disease. After known tick bites and patients with early Lyme disease may be best served by receiving 4 to 6 weeks of antibiotic therapy. Research published in Pmc. Shows that patients with untreated infections may go on to develop chronic, debilitating, multisystem illnesses that is difficult to manage, and numerous studies have documented persistent Borrelia, burgdorferi infection in patients with persistent symptoms of neurological lyme disease following short course. Antibiotic treatment and animal models have demonstrated that short course. Antibiotic therapy may fail to eradicate lyme spirochetes short course is a 1 day. One pill treatment of doxycycline. Or less than 20 days of antibiotics, is considered a short course. It’s not long enough to kill the bacteria. The bacteria’s life cycle is about 21 days, so if you don’t treat the infection long enough, the likelihood of that infection returning is significant. They’ve also done studies in the petri dish, where they show doxycycline being put into a petri dish with active lyme and doxycycline does not kill the infection, it just slows the replication of it. Therefore, using only doxycycline, which is common practice in lyme disease may not completely eradicate that infection for you. So let’s talk about another life threatening emergency. C. Diff clostridia difficile infection, which represents another example where antibiotic treatment is absolutely essential, despite the fact that C diff itself is often triggered by antibiotic use. According to Cleveland clinic C. Diff is estimated to cause almost half a million infections in the United States each year, with 500,000 infections, causing 15,000 deaths each year. Studies reported by Pmc. Found thirty-day Cdi. Mortality rates ranging from 6 to 11% and hospitalized Cdi patients have significantly increased the risk of mortality and complications. Research published in Pmc shows that 16.5% of Cdi patients experience sepsis and that this increases with reoccurrences 27.3% of patients with their 1st reoccurrence experience sepsis. While 33.1% with 2 reoccurrences and 43.2% with 3 or more reoccurrences. Mortality associated with sepsis is very high within hospital 30 days and 12 month mortality rates of 24%, 30% and 58% respectively. According to the Cdc treatment for C diff infection usually involves taking a specific antibiotic, such as vancomycin for at least 10 days, and while this seems counterintuitive, treating an antibiotic associated infection with more antibiotics. It’s often lifesaving. Now let’s talk about preventing devastating complications. Strep throat infections. Provide perhaps the clearest example of when antibiotic treatment prevents serious long-term consequences, and, according to Mayo clinic, if untreated strep throat can cause complications such as kidney inflammation and rheumatic fever. Rheumatic fever can lead to painful and inflamed joints, and a specific type of rash of heart valve damage. We also know that strep can cause pans pandas, which is a systemic infection, often causing problems with severe Ocd. And anxiety and affecting mostly young people. The research is unambiguous. According to the Cleveland clinic. Rheumatic fever is a rare complication of untreated strep, throat, or scarlet fever that most commonly affects children and teens, and in severe cases it can lead to serious health problems that can affect your child’s heart. Joints and organs. And research also shows that the rate of development of rheumatic fever in individuals with untreated strep infections is estimated to be 3%. The incidence of reoccurrence with a subsequent untreated infection is substantially greater. About 50% the rate of development is far lower in individuals who have received antibiotic treatment. And according to the World health organization, rheumatic heart disease results from the inflammation and scarring of the heart valves caused by rheumatic fever, and if rheumatic fever is not treated promptly, rheumatic heart disease may occur, and rheumatic heart disease weakens the valves between the chambers of the heart, and severe rheumatic heart disease can require heart surgery and result in death. The who states that rheumatic heart disease remains the leading cause of maternal cardiac complications during pregnancy. And additionally, according to the National Kidney foundation. After your child has either had throat or skin strep infection, they can develop post strep glomerial nephritis. The Strep bacteria travels to the kidneys and makes the filtering units of the kidneys inflamed, causing the kidneys to be able to unable or less able to fill and filter urine. This can develop one to 2 weeks after an untreated throat infection, or 3 to 4 weeks after an untreated skin infection. We need to find balance. And here’s what I want you to understand. Questioning the medical establishment and developing health literacy doesn’t mean rejecting all medical interventions. It means developing the wisdom to know when they’re necessary and lifesaving versus when they’re unnecessary and potentially harmful. When I see patients with confirmed lyme disease, serious strep infections or life. Threatening conditions like C diff. I don’t hesitate to recommend appropriate therapy but I also work to support their overall health address, root causes, protect and restore their gut microbiome and help them recover their natural resilience. The goal isn’t to avoid all medical interventions. It’s to use them wisely when truly needed, while simultaneously supporting your body’s inherent healing capacity and addressing the lifestyle factors that created the vulnerability. In the 1st place. All of this can be extremely overwhelming, and it can be frightening to understand or learn. But remember, the power that you have is knowledge. The more you learn about what’s actually happening in your health, in understanding nutrition. in learning what your body wants to be fed, and how it feels, and working with practitioners who are holistic in nature, natural, integrative, functional, whatever we want to call that these days. The more you can learn from them, the more control you have over your own health and what I would urge you to do is to teach your children what you’re learning. Teach them how to live a healthy lifestyle, teach them how to keep a clean environment. This is how we take back our own health. So thank you for joining me today on, let’s talk wellness. Now, if this episode resonated with you. Please share it with someone who could benefit from understanding how the Rockefeller medical system has shaped our approach to health, and how to reclaim your body’s wisdom while using medical care appropriately when truly needed. Remember, wellness isn’t just about feeling good. It’s about understanding your body, trusting its wisdom, supporting its natural healing capacity, and knowing when to seek appropriate medical intervention. If you’re ready to explore how functional medicine can help you develop this deeper health knowledge while addressing root causes rather than just managing symptoms. You can get more information from serenityhealthcarecenter.com, or reach out directly to us through our social media channels until next time. I’m Dr. Dab, reminding you that your body is your wisest teacher. Learn to listen, trust the process, use medical care wisely when needed, and take care of your body, mind, and spirit. Be well, and we’ll see you on the next episode.The post Episode 250 -The Great Medical Deception first appeared on Let's Talk Wellness Now.
MEDICARE ADVANTAGE MINUTE: MEDICARE ADVANTAGE OR ORIGINAL MEDICARE: WHICH SHOULD YOU TRUST YOUR HEALTH TO? News items: Older Americans quit weight-loss drugs in droves! Weight-loss pill approved by FDA! This episode ended with our final Christmas Quiz of the season. Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+) Visit us on: BabyBoomer.ORG Inspired by: "MEDICARE FOR THE LAZY MAN 2026; SIMPLEST & EASIEST GUIDE EVER!" "MEDICARE DRUG PLANS: A SIMPLE D-I-Y GUIDE" "MEDICARE FOR THE LAZY MAN: BARE BONES!" For sale on Amazon.com. After enjoying the books, please consider returning to leave a short customer review to help future readers. Official website: https://www.MedicareForTheLazyMan.com.
In this episode of The Truth with Lisa Boothe, Lisa digs into America’s mental health crisis in light of the tragic deaths of Hollywood icon Rob Reiner and his wife Michele — allegedly involving psychiatric medication struggles. Board-certified psychiatrist and former FDA medical officer, Dr. Josef Witt-Doerring joins Lisa to discuss the risks of psychiatric drug over-prescription, hidden side effects of SSRIs and antipsychotics, the impact on youth and developing brains, withdrawal challenges, and how Big Pharma influences the mental health narrative. If you’re curious about the long-term effects of antidepressants, the limits of current research, and how to approach mental health treatment more safely and effectively — this episode is a must-listen. Learn more about Dr. Josef HERESee omnystudio.com/listener for privacy information.
We love to hear from our listeners. Send us a message.In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA). Dr. Putzki walks us through the six-year development journey behind the STEER and STRENGTH Phase 3 programs. And we explore what the expanded age-range label means for patients who were previously left behind, why intrathecal, fixed-dose AAV delivery represents a pivotal advance for safety, efficacy, and scalability. He details how the Itvisma program is informing Novartis' broader gene therapy strategy across neuromuscular and CNS diseases, and more.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
Send us a textIn this episode of Cannabis Legalization News, Tom, a cannabis lawyer, discusses his key predictions for cannabis and hemp legalization in 2026. He outlines three major points: the anticipated rescheduling of marijuana to Schedule 3 and its financial implications for the industry, the potential shutdown of the current hemp market due to new federal definitions and enforcement, and the long-term impact of enhanced research on cannabinoids for medical use. Tom also delves into the timeline for these changes, explaining how actions from Congress, the DOJ, and the FDA will shape the future of cannabis legislation.00:00 Introduction and 2026 Predictions Overview00:28 Understanding Schedule Three and 280E00:50 Debunking Common Misconceptions01:37 Rescheduling Timeline and Industry Impact02:43 Hemp Legislation and Enforcement03:37 Congressional Actions and Deadlines04:35 FDA's Role and New Hemp Definitions06:51 Executive Orders and Regulatory Framework12:58 Research and Medical Use of Cannabinoids15:12 Predictions for 202616:34 Conclusion and Call to ActionSupport the showGet our newsletter: https://bit.ly/3VEn9vu
Today, we're diving into an exciting development in obesity treatment—oral semaglutide. Last week, the FDA approved Novo Nordisk's Wegovy pill as the first and only oral GLP-1 for weight loss in adults. This approval is based on results from the OASIS-4 phase 3 clinical trial showing that a once-daily oral version of semaglutide can deliver nearly the same weight loss results as the injectable form. So, what does that really mean for patients and treatment options? Let's break it down. Read the Full Episode Transcript: https://pepties.com/oral-semaglutide/ Dr. Nikki's Qualifications: https://bifat.life/about/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ BioLongevity Labs (Purchase Peptides online) Use our link and enter COUPON CODE: PEPTIDEPODCAST at checkout to receive 15% off your total order https://go.biolongevitylabs.com/aff_c?offer_id=1&aff_id=1582&aff_sub=PEPTIDEPODCAST Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less. https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1) Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners! ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some fascinating updates that are shaping the future of medicine and healthcare.Let's start with a groundbreaking development in cancer treatment. Researchers have announced significant progress in a novel therapy targeting a specific mutation often found in non-small cell lung cancer. This mutation, known as EGFR exon 20 insertion, has historically been resistant to standard treatments. The new therapy employs a targeted approach that precisely inhibits the mutant protein while sparing normal cells. Early-phase clinical trials have shown promising results, with substantial tumor shrinkage observed in participants. This could potentially redefine treatment protocols for patients who previously had limited options and improve their overall survival rates. As the study progresses into later phases, the industry is watching closely to see if these initial successes translate into long-term benefits.In another significant development, we're seeing advancements in gene therapy for inherited retinal diseases. A recent study has highlighted a novel gene-editing technique that promises to restore vision in patients with certain genetic forms of blindness. By utilizing CRISPR-Cas9 technology, scientists have been able to directly correct mutations in retinal cells. The preclinical models have shown restored function and improved visual responses, paving the way for human trials. This breakthrough is not just a beacon of hope for those affected by genetic blindness but also underscores the transformative potential of gene-editing technologies in treating complex diseases.Moving on to regulatory news, there's an update on new drug approvals that could have widespread implications for public health. The FDA has recently approved a first-in-class drug for the treatment of severe migraines. This medication represents a novel mechanism of action by targeting the calcitonin gene-related peptide (CGRP) pathway, which plays a crucial role in migraine pathophysiology. Clinical trials indicated that it significantly reduces the frequency and severity of migraine attacks compared to existing treatments. For millions of sufferers worldwide, this approval offers a new avenue for relief and highlights the importance of continued innovation in chronic pain management.Shifting gears to vaccine development, there's exciting progress in the fight against infectious diseases. A new vaccine candidate for malaria has shown an unprecedented level of efficacy in trial settings. This vaccine utilizes a protein-based approach that targets multiple stages of the parasite's lifecycle, thereby enhancing its protective effects. Given malaria's devastating impact globally, particularly in sub-Saharan Africa, this development is being hailed as a potential game-changer in global health efforts. As further studies and real-world evaluations unfold, this vaccine could become a cornerstone tool in reducing malaria's burden.Now turning our attention to industry trends, there's growing momentum around personalized medicine and its integration into mainstream healthcare systems. Personalized medicine tailors treatment strategies to individual patient profiles based on genetic, environmental, and lifestyle factors. Recent advances in genomics and data analytics have accelerated this shift, allowing for more precise and effective interventions. For healthcare providers and pharmaceutical companies alike, this trend necessitates rethinking traditional drug development models and embracing collaborative approaches to harness big data effectively.Finally, let's look at an intriguing development in neurodegenerative disease research. Scientists are exploring a new class of drugs designed to target protein misfolding—an underlying cause of conditions Support the show
On this episode of Vitality Radio, Jared sets supplements aside to explore a deeper side of health: emotional vitality and the way we choose to spend our time. Recorded on New Year's Eve, this reflective conversation looks at the inner tension between discipline and desire, purpose and comfort, and why balance matters more than extremes. Drawing inspiration from music, philosophy, and real life, Jared shares insights on identity, attention, and conscious choice — and invites listeners to consider a different question as a new year begins: which part of you are you choosing to bring to life today? This episode is a thoughtful pause before goal-setting begins, offering perspective on growth, meaning, and the life that's still being built.Visit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
The FDA has issued a major safety alert on andexanet alfa, used to reverse factor Xa inhibitors, after post-marketing data and the ANNEXA-I trial showed roughly double the risk of serious and fatal thromboembolic events versus usual care. Concluding that risks now outweigh benefits, U.S. sales will end, forcing hospitals to urgently reassess reversal protocols. Meanwhile, the CDC reports a sharp national rise in influenza activity, dominated by H3N2, with increasing hospitalizations and pediatric deaths; vaccination and early antiviral treatment remain strongly recommended. Finally, the FDA approved once-daily oral semaglutide 25 mg for weight management and cardiovascular risk reduction, offering efficacy comparable to injectable therapy and potentially expanding patient access when launched in 2026.
In today's episode, the discussion features Christof Vulsteke, MD, PhD, head of the Integrated Cancer Center Ghent in Belgium, who provided clinical and regulatory insight into the KEYNOTE-905 study (NCT03924895) and the November 2025 FDA approval of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC). In this exclusive interview, Dr Vulsteke outlined the scientific rationale and study design of KEYNOTE-905, reviewed the key efficacy and safety findings observed with the enfortumab vedotin/pembrolizumab combination, and discussed how the safety profile of this combination aligns with prior experience in bladder cancer. He also contextualized the significance of this FDA approval in addressing a longstanding unmet need for cisplatin-ineligible patients and highlighted remaining gaps in care, including global access, patient selection, and future research directions aimed at improving outcomes in this challenging-to-treat population.
HOW MUCH DO DENTAL IMPLANTS COST!? Download the FREE Guide to Dental Implants Here: https://bit.ly/3YHWmOZWant to know if you may be eligible for Permanent Teeth in 24 Hours? Take the 60-Sec Quiz Here: https://bit.ly/4qJ8Ge7▬▬▬▬▬▬▬▬ Contents of this video ▬▬▬▬▬▬▬▬▬▬Disclaimer: Nuvia Dental Implant Centers are locally owned and operated by licensed dental practitioners. These locally owned and operated practices are part of a professional network of dental implant centers operated by prosthodontists, oral surgeons, and restorative dentists. Each Nuvia Dental Implant Center has a business affiliation with Nuvia MSO, LLC, a Dental Support Organization that provides non-clinical support to each center.*Nuvia Dental Implant Centers are able to provide patients with a bridge made with an FDA approved permanent material, zirconia, in 24-hours. No temporary denture. Not all those who come in for a consultation are medically cleared to receive permanent zirconia teeth in 24-hours. Follow up appointments are required to confirm implant integration and make adjustments if necessary. Results may vary in individual cases. Patients represented in videos are actual NUVIA patient(s) and may have been compensated for their time in telling their story.*While soft foods immediately after surgery are generally approved by our clinical team, the local surgeon may give individual instruction on dental implant aftercare according to the specific circumstances applicable to each case.To hear patient's speech after prosthetic placement please search Nuvia Dental Implant Center on YouTube and watch patient stories.*Individual results may vary based on a number of factors.Copyright 2024. Nuvia Dental Implant Centers. All rights reserved.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating stories that underscore the dynamic nature of our industry, where scientific innovation meets real-world application.Starting with a significant advancement in gene therapy, researchers have made remarkable progress in a novel approach to treating rare genetic disorders. This new methodology involves the use of CRISPR technology to edit genes directly within the human body, paving the way for potential cures once thought impossible. By targeting specific DNA sequences, scientists can now correct genetic mutations at their source. This breakthrough not only promises to transform the treatment landscape for rare diseases but also enhances our understanding of genetic disorders at a molecular level. The implications here extend beyond rare conditions, potentially offering new avenues for tackling more common genetic diseases in the future.Moving forward, let's discuss recent regulatory developments that have caught the industry's attention. The FDA has granted accelerated approval to a new oncology drug that shows promise in treating advanced forms of breast cancer. This decision was based on compelling clinical trial results demonstrating significant improvements in patient survival rates compared to existing therapies. The drug targets specific proteins involved in tumor growth, offering a more precise treatment option with potentially fewer side effects. This approval exemplifies how regulatory bodies are adapting to expedite access to life-saving treatments while ensuring rigorous safety and efficacy standards.In another noteworthy development, a Phase III clinical trial has yielded positive results for a novel Alzheimer's drug. The trial demonstrated that this drug significantly slows cognitive decline in patients with early-stage Alzheimer's disease. By targeting amyloid plaques in the brain, which are believed to contribute to neurodegeneration, this therapeutic approach represents a potential shift in how we treat this debilitating condition. These findings provide hope for millions affected by Alzheimer's and underscore the importance of continued investment in neuroscience research.Turning our attention to infectious diseases, there's exciting news from a biotech company focusing on vaccine development. They've announced encouraging preliminary data from trials of their new mRNA-based vaccine for respiratory syncytial virus (RSV). RSV is known for causing severe respiratory illness, particularly in infants and the elderly. The vaccine demonstrated robust immune responses and a favorable safety profile, suggesting it could become an important tool in preventing RSV infections globally. This development highlights the versatility of mRNA technology, which has already revolutionized COVID-19 vaccine design and holds promise for addressing various infectious diseases.In terms of industry trends, one cannot overlook the growing emphasis on personalized medicine. Recent advancements in biomarker research are enabling more tailored therapeutic approaches across multiple disease areas. By identifying specific genetic or molecular markers associated with diseases, healthcare providers can better predict patient responses to certain treatments. This shift towards precision medicine not only improves patient outcomes but also enhances healthcare efficiency by reducing trial-and-error prescribing.Lastly, we delve into an intriguing area of metabolic disorders where innovative therapeutic strategies are emerging. A biotech firm has developed a first-in-class oral medication for treating non-alcoholic steatohepatitis (NASH), a serious liver condition linked to obesity and metabolic syndrome. The drug works by modulating key metabolic pathways involved in liver inflammation and fibrSupport the show
Support the Institute today: https://givenow.nova.edu/the-institute-for-neuro-immune-medicine-inim-2025 In this episode, Dr. Matthew Halpert and Justin Taylor Hughes join Haylie Pomroy to discuss how immunotherapy can play a critical role in cancer treatment, particularly for patients who may not qualify for clinical trials. Dr. Halpert outlines the clinical process used to support and treat patients, provides an in-depth explanation of immunotherapy and its role in targeting cancer, and discusses the concept of correcting biological dysfunction through biological intervention. Justin shares his personal cancer journey, from exploring multiple treatment modalities to ultimately choosing a holistic and metabolic approach to his diagnosis. He also reflects on his experience with immunotherapy and the importance of spiritual and emotional support for himself and others navigating cancer. Dr. Matthew Halpert, a PhD graduate in Microbiology and Immunology from the University of Alabama at Birmingham (UAB), spent 10 years at Baylor College of Medicine as a leading Cancer Immunologist. His groundbreaking work in cancer immunotherapy has been widely published and cited over 450 times. Dr. Halpert founded Diakonos Oncology, pioneering Dendritic Cell Treatment, which is currently in FDA clinical trials, including a "Fast Track" Glioblastoma trial. In 2021, he established the Immunocine Cancer Center to provide immediate access to this innovative treatment for patients ineligible for trials. Instagram: https://instagram.com/matthalpertphd https://instagram.com/immunocine Facebook - https://www.facebook.com/people/Matt-Halpert/100079347564008/ https://www.facebook.com/Immunocine X- https://x.com/Matthalpertphd https://x.com/ImmunocineCare LinkedIn: https://www.linkedin.com/in/matthew-halpert-b4695174/ https://www.linkedin.com/company/immunocine/ Website: https://immunocine.com Justin Taylor Hughes, born in San Angelo and raised in Bulverde, Texas, is a cancer survivor, author, businessman, and founder of The United Creed, LLC. Diagnosed with cancer during the pandemic, Justin and his wife, Berphy, were supported by a diverse community and are dedicated to promoting unity in America through the principle of "Be Golden." Get Justin's book, "Be Golden" here. https://www.amazon.com/Be-Golden-Unity-Justin-Hughes-ebook/dp/B0CMJ85JB5 Learn more about the United Creed: Website: https://theunitedcreed.com/ Facebook: https://web.facebook.com/unitedcreed?_rdc=1&_rdr X: https://x.com/theunitedcreed Instagram: https://www.instagram.com/united_creed/ LinkedIn: https://www.linkedin.com/company/the-united-creed/ Haylie Pomroy, Founder and CEO of The Haylie Pomroy Group, is a leading health strategist specializing in metabolism, weight loss, and integrative wellness. With over 25 years of experience, she has worked with top medical institutions and high-profile clients, developing targeted programs and supplements rooted in the "Food is Medicine" philosophy. Inspired by her own autoimmune journey, she combines expertise in nutrition, biochemistry, and patient advocacy to help others reclaim their health. She is a New York Times bestselling author of The Fast Metabolism Diet. Learn more about Haylie Pomroy's approach to wellness through her website: https://hayliepomroy.com Instagram: https://www.instagram.com/hayliepomroy Facebook: https://www.facebook.com/hayliepomroy YouTube: https://www.youtube.com/@hayliepomroy/videos LinkedIn: https://www.linkedin.com/in/hayliepomroy/ X: https://x.com/hayliepomroy Enjoy our show? Please leave us a 5-star review on the following platforms so we can bring hope and help to others. Apple Podcasts: https://podcasts.apple.com/us/podcast/hope-and-help-for-fatigue-chronic-illness/id1724900423 Spotify: https://open.spotify.com/show/154isuc02GnkPEPlWfdXMT Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d Enjoy our show? Please leave us a 5-star review on the following platforms so we can bring hope and help to others. Apple Podcasts: https://podcasts.apple.com/us/podcast/hope-and-help-for-fatigue-chronic-illness/id1724900423 Spotify: https://open.spotify.com/show/154isuc02GnkPEPlWfdXMT Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d This podcast is brought to you by the Institute for Neuro-Immune Medicine. Learn more about us here. Website: https://www.nova.edu/nim/ Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM
What do you think of serrapeptase for reducing coronary plaque?We were told to get a TDAP vaccine or we wouldn't be able to see our new grandchild for 8 weeks!Do I have lupus?Which supplements tend to reduce negative effects of X-rays?
The Holiday Season in NYCPeanut allergies cause and effectWhich calcium supplements can I take if I'm allergic to cow protein?Can my husband take saw palmetto in lieu of his prostate medications?What do you think of traction to help bulging discs?What is your take on green powder supplements?
FOREVER Digital Storage - Their mission is to be the complete, permanent, and safe place where millions of families save and enjoy their memories for generations. Please support this sponsor of the podcast.In this episode, we speak with Mark Burnett, founder of My Brain Restore™, about his personal battle with Parkinson's and early Alzheimer's — and the controversial path that followed. My Brain RestoreBurnett discusses:* His diagnoses and the moment he realized standard treatment offered no path to recovery* Why he turned to Japanese neurological research overlooked in Western medicine* The development of his proprietary processing method and why he believes it matters* What he can measure, what he cannot yet prove, and where critics are right to be skeptical* The ethical risks of self-experimentation when the alternative is slow decline* Why FDA limitations complicate public conversations about neurological recoveryThis is not a promotional interview. It is a rigorous, good-faith examination of claims, evidence, and uncertainty, designed to let listeners decide for themselves where they land.Topics Covered:* Parkinson's disease* Alzheimer's disease* Neurodegeneration and brain plasticity* Supplements vs. pharmaceuticals* Evidence standards and clinical trials* FDA regulation and medical claims* Patient-driven innovationImportant Disclaimer:This episode is for informational purposes only and does not constitute medical advice. Always consult licensed medical professionals before making health decisions. Get full access to Melvin E. Edwards at storiesfromreallife.substack.com/subscribe
Frank Yiannas, M.P.H. is a renowned food safety leader and executive, food system futurist, author, professor, past president of the International Association of Food Protection (IAFP), and advocate for consumers. Most recently, he served under two different administrations as the Deputy Commissioner for Food Policy and Response at the U.S. Food and Drug Administration (FDA), a position he held from 2018–2023, after spending 30 years in leadership roles with Walmart and the Walt Disney Company. After retiring from FDA, Mr. Yiannas founded Smarter FY Solutions to help organizations address critical food safety and supply chain challenges. He also advises several well-known companies, offering consultancy services to modernize compliance strategies and ensure that clients meet regulatory requirements and industry standards. Throughout his career, Mr. Yiannas has been recognized for his role in strengthening food safety standards in new and innovative ways, as well as building effective food safety management systems based on modern, science-based, and tech-enabled prevention principles. Drew McDonald is the Senior Vice President of Quality and Food Safety at Taylor Fresh Foods in Salinas, California, where he oversees the quality and food safety programs across the foodservice, retail, and deli operations under both FDA and U.S. Department of Agriculture (USDA) jurisdictions. Mr. McDonald works with an impressive team developing and managing appropriate and practical quality and food safety programs for fresh food and produce products. He has more than 30 years of experience in fresh produce and fresh foods. Over the course of his career, Mr. McDonald has worked with growers and processors of fresh food and produce items across the globe. He currently serves on numerous food safety-related technical committees and has participated in the authorship of many produce safety articles and guidelines. He serves on the Food Safety Summit Educational Advisory Board and is a former chair of the Center for Produce Food Safety's Technical Committee and United Fresh's Technical Council. Mr. McDonald received his education from Lawrence University in Wisconsin. John Besser, Ph.D. worked for ten years as Deputy Chief of the Enteric Diseases Laboratory Branch at the U.S. Centers for Disease Control and Prevention (CDC), where he was involved in national and global programs to detect, characterize, and track gastrointestinal diseases. Prior to CDC, Dr. Besser led the infectious disease laboratory at the Minnesota Department of Health (MDH) for 19 years and served as a clinical microbiologist at the University of Minnesota Hospital for five years. He currently works as an independent contractor and consultant. Dr. Besser is the author or co-author of more than 70 publications. He received his Ph.D. and M.S. degree from the University of Minnesota. Craig Hedberg, Ph.D. is a Professor in the Division of Environmental Health Sciences at the University of Minnesota and Co-Director of the Minnesota Integrated Food Safety Center of Excellence. He promotes public health surveillance as a prerequisite for effective food control, and his work focuses on improving methods for collaboration among public health and regulatory agencies, academic researchers, and industry to improve foodborne illness surveillance and outbreak investigations. With a background in public health practice, Dr. Hedberg also focuses on public health workforce development and works with state, local, and tribal public health partners to build capacity for preparedness and emergency response. He is a member of the Council of State and Territorial Epidemiologists, the Minnesota Environmental Health Association, and IAFP. Dr. Hedberg holds a Ph.D. in Epidemiology and an M.S. degree in Environmental Health, both from the University of Minnesota. In this episode of Food Safety Matters, we speak with Mr. Yiannas, Mr. McDonald, Dr. Besser, and Dr. Hedberg [6:43] about: The increasing rate of food recalls issued by federal regulatory agencies, and what that might imply about the current systems for outbreak investigation and disease surveillance How federal and state public health agencies conduct foodborne illness outbreak investigations and the current success rates of these investigations Elements of the foodborne illness outbreak investigation process that are working well Potential areas for improvement for foodborne illness outbreak investigations and the metrics for "success" An idea for a National Foodborne Outbreak Investigation Board, similar to the model used for airlines with the National Transportation Safety Board, and how such a system might help improve food safety in the U.S. Sponsored by: Michigan State University Online Food Safety Program We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com
This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key trends, and new leadership at FDA shuffled the regulatory deck. On the latest BioCentury This Week podcast, BioCentury's analysts make their picks for the biggest biopharma readouts, deals and regulatory and policy moves of 2025 and what they are forecasting for the year ahead.The analysts also recap biotech highlights of the past two weeks, including the $4.8 billion takeout of Amicus Therapeutics by BioMarin Pharmaceutical.View full story: https://www.biocentury.com/article/657933#BiotechOutlook2026 #BiopharmaTrends #BiotechMA #FDALeadership #ChinaBiotech00:00 - Introduction 02:31 - BioMarin's $4.8B Amicus Deal06:07 - Year-end Biotech Highlights16:37 - Analyst Picks and Predictions30:01 - Policy and Regulatory LandscapeTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Podcast TitleDC EKG with Joe Grogan: A Healthcare Policy Podcast Ep. 122 Healthcare AI Gets Real: Naomi Lopez on ACCESS, TEMPO, and the Future of Care Episode Description-In this episode of DC EKG with Joe Grogan: A Healthcare Policy Podcast, Joe recaps the first Healthcare AI Policy Summit, held on December 10th in Washington, DC, with his co-host for the event, Naomi Lopez, founder of Nexus Policy Consulting. They walk through the big themes shaping healthcare AI right now: how HHS is approaching AI adoption, what real regulatory clarity could look like, and how new federal initiatives like ACCESS and TEMPO may reshape chronic disease management for Medicare patients. Joe and Naomi unpack HHS Deputy Secretary Jim O'Neill's view of AI in government, from using large models to improve physician productivity, payment integrity, and care coordination to managing privacy and re-identification risk when working with federal health data. They dig into the ACCESS Medicare payment model and the FDA TEMPO initiative, explaining how these pilots test AI and machine learning tools in real-world chronic disease management (hypertension, diabetes, musculoskeletal pain, and depression), and what that means for Medicare payment models, FDA oversight, and healthcare innovation. The conversation then widens to physician burnout, interoperability, rural care, and the role of states and federal preemption in setting the rules for healthcare AI. If you care about the real-world impact of healthcare AI on policy, payment, and patients, this episode offers a clear, practical summary of what the summit revealed and what to watch next. Today Joe and Naomi cover: Jim O'Neill's vision for AI at HHS, including internal AI adoption and keeping a direct line open for small innovators. ACCESS and TEMPO as new federal test beds for AI in chronic disease management and Medicare payment. How wearables, remote monitoring, and “virtual ICU” models can support aging in place and reduce pressure on state budgets. Ways AI can reduce documentation burden, support care coordination, and act as a first-line triage tool without replacing clinicians. The emerging idea of personal AI agents that help patients navigate the system and share the right data with clinicians. How AI-enabled diagnostics and tools can expand access in rural and underserved communities. Why interoperability, ONC's API rules, and the balance between state AI regulation and federal preemption will shape how quickly these tools scale. The potential for tech companies to become Medicare Part B providers under ACCESS, and what that means for reimbursement and competition. Key Takeaways: Healthcare AI is being built into policy through programs like ACCESS and TEMPO, tying AI tools to Medicare payment and FDA pathways in chronic disease management. Regulatory clarity and predictable routes from FDA clearance to Medicare reimbursement are essential for sustained AI adoption. AI is currently most valuable as a force multiplier for physician productivity, taking on administrative and analytic work so clinicians can focus on patients. Personal AI agents may become a primary interface between patients and the health system, coordinating data, benefits, and care. Rural and underserved communities could benefit significantly if payment and regulatory rules support AI-enabled diagnostics and remote care. Interoperability, state AI laws, and federal preemption will determine whether healthcare AI stays in pilots or reaches patients nationwide. Naomi Lopez is the founder of Nexus Policy Consulting and a leading voice in healthcare policy, healthcare AI, and state health reform. She co-founded a healthcare AI working group with Joe Grogan and co-hosted the inaugural Healthcare AI Policy Summit on December 10th in Washington, DC.
Nausea shouldn't be the most memorable part of surgery. We take a clear, evidence-based look at postoperative nausea and vomiting, from identifying who's at risk to building smarter prophylaxis bundles and choosing the right rescue when prevention falls short. With guest insights from Dr. Connie Chung, we unpack the Fourth Consensus Guidelines, translate them into practical workflows, and explore how Amisulpride—an atypical D2 antagonist—changes the game with an FDA indication for rescue after failed prophylaxis.We start by shrinking baseline risk: consider regional anesthesia when feasible, leverage TIVA with propofol, avoid nitrous and volatiles in longer cases, hydrate well, and spare opioids with multimodal analgesia. Then we scale prophylaxis to risk: dexamethasone at induction, 5-HT3 antagonists at the end, transdermal scopolamine for select patients, and low-dose Droperidol where appropriate. When prophylaxis fails, we explain why repeating ondansetron rarely helps and how switching classes boosts rescue success. Along the way, we map the safety terrain for D2 antagonists—QT prolongation, extrapyramidal risks, anticholinergic effects—so you can individualize care for elderly patients, those on antipsychotics, or anyone with potential drug interactions.We also dig into what's new: contemporary analyses of Droperidol at antiemetic doses, and growing evidence that Amisulpride pairs well with Ondansetron or Dexamethasone to improve outcomes. Pediatric pearls include TIVA, fluids, and a two-drug prophylaxis backbone for longer or higher-risk cases. The result is a practical, stepwise approach you can apply tomorrow—reduce risk, layer mechanisms, and rescue smartly—to cut PACU delays, avoid unplanned admissions, and deliver a recovery that feels as good as the surgical fix.If this deep dive helps your practice, follow, share with your team, and leave a quick review to help others find the show. Tell us your go-to PONV bundle and whether your site stocks Amisulpride.For show notes & transcript, visit our episode page at apsf.org: https://www.apsf.org/podcast/287-a-new-era-for-ponv-safety-guidelines-and-smarter-rescue/© 2025, The Anesthesia Patient Safety Foundation
Blake Lynch aka Nurse Blake joins the pod for a revealing chat. From being forced to undergo conversion therapy by his parents, to his recent public divorce from his long-time partner, Nurse Blake gets real about everything! Nurse Blake details how his traumatic childhood inspired him to get into nursing, and how it oddly led to a viral comedy career and sold-out world tour. Nurse Blake gets candid about patients attacking nurses, fighting the FDA for 10 years to get the blood donation ban against bi and gay men repealed, and his NurseCon cruise ship setting sail to Jamaica in 2026.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we dive into the latest breakthroughs and innovations shaping our industry. We start with a remarkable advancement in Alzheimer's disease treatment. A recent clinical trial has demonstrated significant progress in slowing cognitive decline among patients suffering from this challenging condition. The study, which involved a novel monoclonal antibody, showed promise by targeting amyloid plaques, a hallmark of Alzheimer's pathology. This approach not only opens new avenues for treatment but also provides hope for millions of patients and their families. The scientific community is closely monitoring these developments as they could redefine therapeutic strategies for neurodegenerative diseases.Moving on to regulatory news, the FDA has recently granted approval to a groundbreaking gene therapy for hemophilia B. This therapy represents a significant milestone as it offers a potential one-time treatment to correct the genetic defect underlying the disorder. By delivering a functional copy of the gene necessary for clotting factor production, patients may experience reduced bleeding episodes and improved quality of life. This approval underscores the FDA's commitment to advancing personalized medicine and highlights the transformative potential of gene therapies in addressing rare genetic conditions.In oncology, we've seen exciting progress with a novel targeted therapy showing efficacy in treating advanced stages of lung cancer. The drug specifically inhibits a mutation found in non-small cell lung cancer, which is often resistant to conventional treatments. Clinical trials have reported improved survival rates and better tolerability compared to existing therapies, marking a significant step forward in precision oncology. As researchers continue to unravel the complexities of cancer genomics, targeted therapies like this one offer new hope for patients battling aggressive forms of cancer.The biotech industry is also witnessing a surge in collaborations aimed at expediting vaccine development. In light of recent global health challenges, several companies have entered strategic partnerships to leverage their combined expertise in mRNA technology. These collaborations aim to accelerate the production and distribution of vaccines for infectious diseases beyond COVID-19. By pooling resources and sharing technological advancements, these alliances have the potential to enhance our preparedness for future pandemics and improve global public health outcomes.Shifting focus to autoimmune diseases, a novel small molecule inhibitor has shown potential in managing rheumatoid arthritis symptoms more effectively than traditional treatments. This new drug targets specific pathways involved in inflammation without compromising immune function. Early clinical data suggests it could offer patients relief with fewer side effects, representing a promising addition to the therapeutic arsenal against chronic inflammatory conditions.In an intriguing development within regenerative medicine, researchers have made strides in bioengineered organs. A recent breakthrough involves creating functional liver tissue from stem cells, paving the way for future organ transplantation solutions. These lab-grown tissues have demonstrated essential liver functions in preclinical models, bringing us closer to addressing organ shortages and enhancing transplant success rates. The implications of such advancements extend far beyond liver disease, offering transformative possibilities for regenerative therapies across various medical fields.Turning our attention to antimicrobial resistance, an ever-pressing concern within global health, scientists have discovered a new class of antibiotics capable of combating multidrug-resistant bacteria. This discovery comes atSupport the show
On today's Good Day Health Show - ON DEMAND…Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken begin with what he sees from patients after the first of the year. Primarily, part of New Year's Resolutions include a focus on health, with people coming into the doctor's office more often to check in on their health, especially with the overindulgence from the holiday season. January, in general, is a time of huge interest in one's health. Then, the conversation shifts to a lab-grown heart, creating hopeful treatments for the future to regrow human organs. Continuous research and trials are intended to lead to successful transplants without needing donor waiting lists. Next up, Doug and Dr. Ken dive into Myasthenia Gravis (MG), a chronic autoimmune disease causing fluctuating weakness in voluntary muscles (eyes, face, swallowing, limbs) that worsens with activity and improves with rest, due to nerve signals being blocked from reaching muscles by the immune system. There is now a FDA approved treatment offering new hope to patients with MG. Shifting focus to mental health, a review finds some patients are able to safely taper off some of the antidepressants, a new hope following criticism that once you got on these drugs you can't get off of them. Rounding out the conversation, listener questions are addressed, including the dangers of hair loss pills and potential benefits of topicals over consumed OTC or prescribed medications, surprising benefits of vitamin D that go beyond bone health, if women should exercise differently than men or if age matters more than sex, and more. Website: GoodDayHealthrShow.com Social Media: @GoodDayNetworks
Kratom and 7-OH products are available in many smoke shops. But earlier this year, the FDA recommended certain 7-OH products be scheduled alongside opioids. This isn't the first time kratom has come under scrutiny. Nearly a decade ago, the DEA wanted to make certain active ingredients in kratom controlled substances. Meaning products would go from being widely available to highly restricted. After a massive wave of protest, the DEA decided not to move forward. Producer Rachel Carlson joins host Emily Kwong to talk about what could happen this time around, and what scientists know – and don't know – about kratom and 7-OH. Interested in more of the science behind drugs and supplements? Email us your question at shortwave@npr.org.Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy
Episode Description In this year-end episode, Chris Wolfe, OD takes a step back from protocols, products, and positioning statements to examine a more fundamental question in clinical care: when does belief help us act, and when does belief get ahead of the data? Throughout the year, we've emphasized that belief during the comprehensive exam is what drives action. If doctors and teams do not truly believe something matters, it does not get prioritized. But belief has a failure mode. When belief outpaces evidence, especially in pediatric care, it can distort expectations, decision-making, and policy. Using the FDA's decision on low-dose atropine as a case study, this episode explores how belief forms, how it spreads, and where it may diverge from what the publicly available data actually show. This is not an argument against myopia management or atropine therapy. It is an attempt to slow the conversation down and examine effect size, study design, endpoints, and uncertainty with clarity and humility. What You'll Learn in This Episode Why myopia management itself is not the controversy, but certainty often is How belief influences behavior in the comprehensive exam, for better and for worse What the FDA actually said in its Complete Response Letter on SYD-101 How professional statements and press releases can amplify belief beyond available data What the STAR trial poster does and does not show, including effect size and subgroup uncertainty Why modest effect sizes behave differently in real-world clinical practice How to think about dose, endpoints, and population selection without oversimplifying Why belief should motivate action, but evidence should calibrate expectations Key Sources Referenced in This Episode FDA and Manufacturer Statements Sydnexis Complete Response Letter Press Release Sydnexis Receives Complete Response Letter from FDA for SYD-101 to Slow Pediatric Myopia Progression https://www.sydnexis.com/news/sydnexis-receives-complete-response-letter-from-fda-for-syd-101 Sydnexis Phase III STAR Trial Topline Data Press Release Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial https://www.sydnexis.com/news/sydnexis-announces-topline-pivotal-data-from-phase-3-star-trial UK Approval Announcement (Based on STAR Data) Sydnexis Announces UK Approval of Ryjunea by Partner Santen https://www.sydnexis.com/news/sydnexis-announces-uk-approval-of-ryjunea Professional Organization Statements AAOMC Public Statement AAOMC Calls for Access to Proven Myopia Therapies as Low-Dose Atropine Gains Global Approvals https://aaomc.org AAPOS Commentary on Nonapproval of SYD-101 Available via LinkedIn and Healio OSN Clinical Commentary and Analysis Kyle Klute, OD – Optometry Simplified My Alternative Take on Atropine, Fast Progressors, and Effect Size (NNT Analysis) https://optometrysimplified.com/posts/optometry-simplified-weekly-my-alternative-take-on-atropine-fast-progressors-in-glaucoma-lab-test-ordering-and-more Strongly recommended for a detailed discussion of effect size and Number Needed to Treat. This episode references Kyle's framework without reproducing his calculations. Review of Myopia Management – Ashley Wallace Tucker, OD What Does the FDA Decision on SYD-101 Mean for Eye Care? Review of Optometry – Paul Karpecki, OD Sydnexis Snubbed Review of Optometry – Cory Lappin, OD Optometric Physician Commentary on SYD-101 Healio OSN – Ed Wilson, MD and John Hovanesian, MD AAPOS: Nonapproval of SYD-101 Has Important Implications Why This Episode Matters This episode is not about picking sides. It is about learning to sit in uncertainty without abandoning action. It challenges listeners to examine where belief helps patient care and where belief may unintentionally replace careful analysis. If you manage myopia, counsel parents, interpret clinical trials, or influence policy, this episode is designed to help you think more clearly, not more loudly. Connect and Continue the Conversation If this episode resonated with you, or if you found yourself uncomfortable in parts of it, that reaction is worth exploring. Thoughtful medicine requires both conviction and restraint. ------------------- For our listeners, use the code 'EYECODEMEDIA22' for 10% off at check out for our Premiere Billing & Coding bundle or our EyeCode Billing & Coding course. Sharpen your billing and coding skills today and leave no money on the table! questions@eyecode-education.com https://coopervision.com/myopia-management Go to MacuHealth.com and use the coupon code PODCAST2024 at checkout for special discounts Show Sponsors: CooperVision MacuHealth
Space startups today look a lot like the internet in 1995 – early, chaotic, and packed with upside for the founders brave enough to build in the void. With VCs going all in on space, Techstars betting big on the category, and an entire industry quietly taking over venture capital, this is a moment founders can't ignore.In this episode of Demo Day, Techstars Space Managing Director Gabriel Schlumberger breaks down why “SPACE IS THE FUTURE” is more than a catchy thumbnail – it's an actual investing thesis. Gabriel explains how launch costs, new business models, and a surge of satellites are turning space into one of the most important frontier markets for startups and venture capital.Gabriel shares his journey from Pixar, Blue Sky, and Disney to becoming a founder himself, building an FDA‑regulated glasses startup for kids in the middle of a global pandemic, and then stepping into his role at Techstars Space. That experience across creative studios, corporate innovation, and true zero‑to‑one startup chaos shapes how he now evaluates founders and why he's so bullish on space companies.You'll learn:Why space today feels like the internet did in 1995, and what that means for startup timing and upside.How Techstars is betting big on space through its accelerator with NASA JPL and the U.S. Space Force.The trait Gabriel calls “pathological curiosity” and why it separates the best founders and VCs.What actually happens inside Techstars: mentor weeks, “give first” culture, and how a few teams get picked from hundreds of applicants.A real founder story: running a hardware and medical device startup through COVID, fundraising, manufacturing, and brutal unknowns.Whether you're a founder thinking about space, a SaaS builder curious about frontier markets, or an investor trying to understand the industry quietly taking over VC, this episode is a masterclass in how the next decade of startups will be built.
This Doctales with Cocktails episode veers from absurd to deadly serious—and back again. What starts with Kim Kardashian's “Ultimate Bush” spirals into a surprisingly historical discussion of pubic wigs, cultural aesthetics, and performative sexuality. From there, the tone shifts hard as a bombshell FDA letter challenges the foundations of modern vaccine approval, exposing reliance on surrogate endpoints, weak evidence, and ignored harms—especially in children.The episode then detonates another cultural landmine: the outrage over the word retarded. The conversation digs into how language becomes weaponized, how offense is outsourced, and why words that once described reality are now treated as moral crimes. The show closes on a rare reflective note—contrasting anger-driven discourse with joy, purpose, and meaning—highlighted by the story of a man who skied joyfully for nearly a century. GET SOCIAL WITH US!
In today's episode, your host, Jon LaClare, leads an important conversation that healthcare marketing rarely explains: the placebo effect and why it deserves far more attention. This discussion is inspired by the launch of Pluseebo, a transparent, intentionally humorous product designed to spark awareness around belief, expectation, and honesty in healthcare.While Pluseebo is lighthearted on the surface, its launch highlights a much deeper reality supported by published scientific research. Placebo responses can produce real, measurable biological effects in the body, including changes in brain chemistry, pain perception, and overall wellbeing. These effects are not imagined, and in many clinical trials they closely mirror the average performance of widely prescribed medications.Tune in as Jon breaks down what healthcare advertising often leaves out, including how modest the average benefit of some antidepressants, pain medications, sleep aids, and other common prescriptions can be when compared to placebo, and why side effects and transparency must be part of the conversation. Grounded in respected medical journals and FDA-reviewed data, this episode offers a research-driven perspective designed to inform, challenge assumptions, and elevate the discussion around modern healthcare. Don't miss this timely conversation on belief, biology, and why understanding the placebo effect changes how health products, treatments, and claims should be evaluated.In today's episode of the Harvest Growth Podcast, we'll cover:What the placebo effect actually is, and why it's not “fake.”What large studies reveal about SSRIs, opioids, sleep medications, anxiety medications, ADHD drugs, and statins.Why prescription drug commercials rarely tell the full storyHow transparency in healthcare affects trust and decision-makingHow Pluseebo is designed to spark honest conversations.To learn more about Pluseebo, visit Pluseebo.com.To be a guest on our next episode of the podcast, contact us today!Do you have a brand that you'd like to launch or grow? Do you want help from a partner that has successfully launched hundreds of brands totaling over $2 billion in revenues? Visit HarvestGrowth.com and set up a free consultation with us today!
Start making $150k - $200k+ in your first year of medical sales. Stop chasing crowded "old school" roles like Orthopedics and Spine. The real money—and the life-saving innovation—is in Oncology and Specialty Pharma. Today, I reveal the exact blueprint to reinvent your career and break into the most lucrative sector of healthcare. Whether you're a nurse, a teacher, or stuck in a "middle-class mindset," this episode breaks down why your background doesn't matter. Only your preparation does.I share my personal journey from a non-profit minister making $70k to a high-level oncology rep, and explain why "casual advice" from friends will get you rejected. If you want to master the interview, crush your clinical knowledge, and build a 6-figure life, this is the masterclass you need.WHAT YOU WILL LEARN IN THIS EPISODE:- The "Gold Rush" Shift: Why you should ignore Orthopedics and focus entirely on Oncology, Diagnostics, and Genetic Testing.- The 3 Essential Mindset Shifts: How to move from "winging it" to becoming an obsessively prepared candidate.- Real Success Stories: How Kanika (immigrant to Dallas), Sydney (nurse), and others went from zero experience to $200k roles.- The "Ride-Along" Trap: Why you need a brutal coach, not a nice mentor.- The HEART Framework: The 5 character traits (Humility, Energy, Active Listening, Resilience, Trust) that hiring managers look for.- Confidence vs. Arrogance: How to show "grit" without sounding like a jerk.- Daily Habits of Top 1% Earners: The 5 AM club, the "20 LinkedIn adds" rule, and why your degree (MBA) has a lower ROI than coaching.- The Michael Jordan Rule: Why even the greatest of all time hired coaches for their specific weaknesses.TIMESTAMPS00:00 - Introduction: The Program Focus (Oncology vs. Orthopedics)01:34 - Dave's Story: Reinventing Career from Ministry to Medical Sales03:44 - Success Stories: How Nurses & Immigrants Got Hired (Kanika, Sydney)06:47 - Mindset Shift #1: Be Coachable (Why Friends Can't Help You)09:20 - Mastering Virtual Interviews (Lighting, Camera & Background)10:32 - Mindset Shift #2: Be Curious (Understanding Clinical Trials & FDA)12:32 - Salary Reality: Device Associate ($80k) vs. Oncology ($155k+)13:55 - Mindset Shift #3: Collaboration (Working with MSLs & Nurse Navigators)16:28 - Confidence vs. Arrogance (The "Grit" Trap)18:02 - The H.E.A.R.T. Framework (Humility, Energy, Listening, Resilience, Trust)19:00 - Daily Habits: 5 AM Wake-ups, LinkedIn Strategy & Handling Rejection20:00 - The"Middle Class Mindset" Trap: Why Degrees Have Low ROI22:25 - Using AI for Resumes Without Sounding Like a Robot25:55 - The "Why": Patient Outcomes & Life-Extending Impact29:35 - The 3 Questions You Must Ask Yourself31:01 - The Michael Jordan Analogy: Why Even the Best Hire Coaches.ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US: Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #OncologySales #CareerPivot #SalesCoaching #HighIncomeSkills #DaveSterrett #MedicalSalesYou #InterviewTips #SalesJobs #PharmaceuticalSales
Send us a message with this link, we would love to hear from you. Standard message rates may apply. Oral Wegovy is officially FDA approved — but what does that actually mean for patients? In this episode of Your Checkup, we break down the December 2025 approval of oral semaglutide 25 mg for chronic weight management, who qualifies, how it works, and how effective it really is. We review the clinical trial data behind the approval, including expected weight loss, common side effects, and long-term expectations, and explain how oral Wegovy compares to injectable GLP-1 medications. We also tackle common misconceptions, dosing and lifestyle considerations, and the very real challenges of cost and insurance coverage. If you've heard the headlines and want the facts — without hype — this episode is for you. Check out our new graphics. Thank you, Vantage Design Works. Check out our website, you can send us an email, yourcheckuppod@gmail.com. Check out our website, you can find us on Instagram, share us with a friend or a neighbor. But most importantly, stay healthy, my friends.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN Artwork Rebrand and Avatars: Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/ Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr Original Artwork Concept: Olivia Pawlowski
Coach Love Agudo is VP for Product Formulation at Kanzen Barley. Tita Joy Nuska is VP for Finance at Kanzen Barley.Kanzen Barley is the first Japan-patented postbiotic barley in the Philippines, FDA registered and backed by clinical studies, delivering ultimate immunity for everyday health.This episode is recorded live at Yspaces Co-Working and Event Space in BGC, Taguig. Yspaces is the official co-working and event space partner of Start Up Podcast PH.In this episode:00:00 Introduction00:47 Ano ang Kanzen Barley?06:58 What problem is being solved? 15:07 What solution is being provided? 25:21 What are stories behind the startup? 41:37 What is the vision? 44:44 How can listeners find more information?KANZEN BARLEYFacebook: https://facebook.com/kanzenbarleyYSPACESWebsite: https://knowyourspaceph.comFacebook: https://facebook.com/yspacesphTHIS EPISODE IS CO-PRODUCED BY:Yspaces: https://knowyourspaceph.comApeiron: https://apeirongrp.comTwala: https://twala.ioSymph: https://symph.coSecuna: https://secuna.ioSkoolTek by Edfolio: https://skooltek.coMaroonStudios: https://maroonstudios.comCompareLoans: http://compareloans.phCHECK OUT OUR PARTNERS:Ask Lex PH Academy: https://asklexph.com (5% discount on e-learning courses! Code: ALPHAXSUP)Argum AI: http://argum.aiPIXEL by Eplayment: https://pixel.eplayment.co/auth/sign-up?r=PIXELXSUP1 (Sign up using Code: PIXELXSUP1)School of Profits: https://schoolofprofits.academyFounders Launchpad: https://founderslaunchpad.vcHier Business Solutions: https://hierpayroll.comAgile Data Solutions (Hustle PH): https://agiledatasolutions.techSmile Checks: https://getsmilechecks.comCloudCFO: https://cloudcfo.ph (Free financial assessment, process onboarding, and 6-month QuickBooks subscription! Mention: Start Up Podcast PH)Cloverly: https://cloverly.techBuddyBetes: https://buddybetes.comHKB Digital Services: https://contakt-ph.com (10% discount on RFID Business Cards! Code: CONTAKTXSUP)Hyperstacks: https://hyperstacksinc.comOneCFO: https://onecfoph.co (10% discount on CFO services! Code: ONECFOXSUP)Wunderbrand: https://wunderbrand.comDVCode Technologies Inc: https://dvcode.techNutriCoach: https://nutricoach.comUplift Code Camp: https://upliftcodecamp.com (5% discount on bootcamps and courses! Code: UPLIFTSTARTUPPH)START UP PODCAST PHYouTube: https://youtube.com/startuppodcastphSpotify: https://open.spotify.com/show/6BObuPvMfoZzdlJeb1XXVaApple Podcasts: https://podcasts.apple.com/us/podcast/start-up-podcast/id1576462394Facebook: https://facebook.com/startuppodcastphPatreon: https://patreon.com/StartUpPodcastPHPIXEL: https://pixel.eplayment.co/dl/startuppodcastphWebsite: https://phstartup.onlineThis episode is edited by the team at: https://tasharivera.com
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some fascinating breakthroughs and regulatory updates that are shaping the future of healthcare.Starting with a pivotal advancement in Alzheimer's research, a new drug has shown promising results in slowing cognitive decline in patients with early-stage Alzheimer's disease. This innovative therapy targets amyloid plaques in the brain, which are believed to play a central role in the progression of Alzheimer's. Recent clinical trials have demonstrated that patients receiving this treatment experienced a significant reduction in the rate of cognitive deterioration compared to those on a placebo. The implications of this development are profound, offering hope for millions affected by this debilitating condition. As researchers continue to unravel the mysteries of Alzheimer's, this breakthrough marks a crucial step forward in understanding and potentially halting disease progression.Moving on to regulatory news, the FDA has recently granted accelerated approval to a novel gene therapy for a rare genetic disorder known as spinal muscular atrophy (SMA). This condition, which affects motor neurons and leads to muscle wasting and weakness, primarily impacts infants and young children. The newly approved therapy works by delivering a functional copy of the defective gene directly into the patient's cells. Early trials have shown remarkable improvements in motor function and survival rates among treated infants. This approval represents not only a lifeline for affected families but also underscores the growing potential of gene therapies to address previously untreatable genetic diseases.In another significant development, researchers have unveiled a groundbreaking study on an experimental cancer vaccine that has demonstrated efficacy in preventing tumor growth in preclinical models. Unlike traditional vaccines aimed at infectious diseases, this cancer vaccine is designed to harness the body's immune system to specifically target and destroy cancer cells. The study's results indicate that the vaccine was successful in generating a robust immune response, which significantly inhibited tumor progression. If these findings can be replicated in human trials, it could open new avenues for cancer prevention and treatment, particularly for cancers with limited therapeutic options.Shifting our focus to trends within the industry, there's an increasing emphasis on personalized medicine, reflecting a broader shift towards treatments tailored to individual patients' genetic profiles. This approach aims to optimize therapeutic efficacy while minimizing adverse effects by considering each patient's unique genetic makeup. Advances in genomic sequencing technologies and bioinformatics are driving this transformation, enabling more precise diagnostics and targeted therapies. As personalized medicine continues to evolve, it holds the promise of revolutionizing how diseases are treated and managed in clinical practice.On the topic of drug approvals, a new oral medication for type 2 diabetes has received regulatory clearance after demonstrating superior glycemic control compared to existing treatments. This drug belongs to a novel class of medications that enhance insulin sensitivity and reduce glucose production by targeting specific metabolic pathways. Clinical trials indicated significant improvements in blood sugar levels and overall metabolic health among participants. Given the global prevalence of type 2 diabetes and its associated health complications, such advancements are crucial for improving patient outcomes and reducing healthcare burdens.Lastly, focusing on collaborations within the industry, several prominent pharmaceutical companies have announced partnerships aimed at accelerating research in infectious diseases.Support the show
A new GLP-1, weight loss pill has been approved by the FDA. We take a look at what this means and how GLP-1 drugs work with Dr. Mace Scott, founder of Chronos Wellness.
Mayo Clinic's Dr. Sundeep Khosler discusses findings from the first major randomized controlled trial of senolytics in humans, revealing why cellular aging varies dramatically between individuals and what this means for longevity interventions.Dr. Sundeep Khosler, a physician-researcher at the Mayo Clinic, leads some of the first human clinical trials testing senolytics for aging and age-related diseases. In this conversation, he shares critical findings from their 60-person randomized controlled trial that challenge assumptions about how we age at the cellular level.The study revealed that senescent cell burden varies dramatically between individuals, with significant implications for who might benefit from senolytic interventions. While overall results showed modest improvements in bone formation markers, women with the highest senescent cell burden (measured through blood biomarkers) showed dramatic 60% improvements—suggesting aging interventions may require personalized approaches rather than universal protocols.Dr. Khosler discusses the development of blood-based biomarkers for measuring senescent cell burden, explains why age 70 appears to be a critical threshold, and addresses the gap between promising animal studies and human translation. He provides evidence-based guidance on what people can do now, explains why he doesn't recommend current senolytics outside clinical trials, and discusses FDA-approved medications that may impact cellular aging as secondary benefits.This interview offers a balanced, nuanced perspective on where senolytic research actually stands, moving beyond hype to understand both the promise and limitations of targeting senescent cells for healthspan.
Trump's act of war against Venezuela - US exactly like pirates :: Trump's executive order telling the FDA to reschedule weed to a lower level :: Have ICE deaths gone up? :: ISPs may be forced to kick users off for piracy :: Trump actually stands up to EU for trying to encroach on Free Speech :: Keeping Bitcoin in a roth IRA :: TSA giving names and photos of everyone to ICE :: the Fed to end paper checks :: 2025-12-27 Hosts: Bonnie, Angelo, Mr.Penguin
On this episode, Jared and Jen break down one of the most misunderstood hormone issues affecting both women and men: estrogen dominance. This isn't always about having “too much estrogen”—it's about a ratio problem, driven largely by low or depleted progesterone. You'll learn how estrogen is metabolized through different liver pathways, why some forms of estrogen are far more disruptive than others, and how liver health, gut function, stress, blood sugar, and environmental exposures all shape hormone balance. The episode also explores how estrogen dominance shows up differently in women and men, why symptoms often persist even when labs look “normal,” and how modern lifestyle factors quietly stack the deck against hormonal health.Jared and Jen also take an honest look at hormonal birth control, endocrine disruptors, seed oils, and genetic factors that can impair estrogen clearance—without fear-mongering or oversimplification. The episode closes with a clear, practical framework for supporting estrogen metabolism, restoring progesterone balance, and addressing the root causes naturally.Products:LiverVitalityEndoCleanseBack on TractVital D3/K2Ultimate Vitality MultiActive B ComplexMagnesium BisglycinateAdditional Information:#588: The Hidden Epidemic Part 1: How Endocrine Disruptors Are Hijacking Your Health#589: The Hidden Epidemic Part 2: The Complete Endocrine Detox Strategy#595: The Estrobolome Explained: How Your Gut Shapes Your HormonesCheck out all five“Jen's Story” Episodes!Dirty Genes - Book by Dr. Ben LynchVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
It's an encore presentation of one of our favorite episodes! Ali's very special guest today is Elizabeth Carr, the first person born in the U.S. — in 1981 — via in vitro fertilization. "My birth was so widely publicized that my first press conference was at three days old," Elizabeth says. "I didn't get here like everybody else." Elizabeth shares what it's been like to live under media scrutiny since the moment she was born (check out the NOVA documentary about her life). She also explains why her parents did IVF in the first place, what the IVF landscape was like back then, how the actual procedure worked (so much has changed!) and the incredible work she's doing today to advocate for IVF and reproductive rights. She also shares how the pope, when she was born, called her "a child of the devil." For more, check out https://ejordancarr.com/ and her IG: @ejordan12 EPISODE SPONSORS: THE WORK OF ART BOOK SERIESAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe latest book in the Work of ART series, “You Are a Work of ART," is for every kiddo born through ART -- and the people who love them.Order "Work of ART," "Beautiful Bird" and "You Are a Work of ART," now at https://www.infertileafgroup.com/booksFERTILITY RALLYIG: @fertilityrallywww.fertilityrally.comNo one should go through infertility alone. Join the Worst Club with the Best Members at fertilityrally.com. We offer 5 to 6 support groups per week, three private Facebook groups, tons of curated IRL and virtual events, and an entire community of more than 500 women available to support you, no matter where you are in your journey.Join today at link in bio on IG @fertilityrally or at www.fertilityrally.com/membershipPHERDALIG: @pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Go to PherDal.com today and use code INFERTILEAF for $10 off.BELIIG: @belibabywww.belibaby.com Are you thinking about growing your family? Whether you're just starting to plan or are actively trying to conceive, preconception health is key. Beli has vitamins to help both women and men optimize their health before pregnancy. With essential nutrients like Folate, Iodine, and Zinc, Beli ensures your body is ready for this exciting next step. Give yourself and your future baby the best foundation for a healthy start.Visit Belibaby.com today and use code IAF15 for 15% off your first order. Support this podcast at — https://redcircle.com/infertile-af-infertility-and-modern-family-building-through-art/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article: A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14 "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01
This week we welcome double board-certified dermatologist AND dermatopathologist, Dr. Aegean Chan to bridge the gap between medical dermatology and your daily skincare routine. Tapping her clinical expertise in medical dermatology, skin cancer and acne, we unwrap Dr. Chan's professional insights on the skin barrier, sun protection, and why she believes we should be wary of "anec-data" especially when it comes to a $400 serum.In this week's episode, we discuss: How truly complex the skin barrier is (as she sees it under a microscope), and why it's the foundation of great skinHoliday break ready! Which sunscreen Dr. Chan personally buys in bulkTruth bombs about Vitamin C! Why Dr. Chan doesn't think this hero ingredient is right for everyoneWhy she *doesn't* think shopping for skincare based on a pH level is a necessary strategyWhat Dr. Chan makes of transdermal patches for skincare – are they the future of youthful skin?Plus: Should we rethink trending, in-office procedures like radiofrequency combined with microneedling per recent FDA guidelines? For any products or links mentioned in this episode, check out our website: https://breakingbeautypodcast.com/episode-recaps/ Get social with us and let us know what you think of the episode! Find us on Instagram, Tiktok,X, Threads. Join our private Facebook group. Or give us a call and leave us a voicemail at 1-844-227-0302. Sign up for our Substack here. Subscribe to our YouTube Channel to watch our episodes! Related episodes like this: Derm Hot Takes! The Real Deal on Those Viral Hypochlorous Acid Skin Sprays, the Most Legit At-Home Skincare Devices and the Unsexy Vitamin C Serum You Need To Know About NowAre You Applying Your Sunscreen the Right Way? Plus Myth-Busting Those Rage-Bait SPF Headlines, Tanning on Trial and More With Board-Certified Dermatologist Dr. Michelle HenryDr. Muneeb Shah aka @DermDoctor On Starter Skincare Routines For Aging Skin, The New Accutane-Alternative For Acne and Should You Mix Your Rx Retinol With Drugstore Moisturizer?? PROMO CODES: When you support our sponsors, you support the creation of Breaking Beauty Podcast! SeedGet ahead of the New Year with a routine that helps you now by going to Seed.com/BEAUTY and use code BEAUTY to get 20% off your first month of Seed's DS-01® Daily Synbiotic.Curology Enjoy our limited-time holiday offer — a personalized prescription FREE with your subscription, all you pay is $5.45 shipping and handling! To claim this offer, go to curology.com/beauty to take Curology's skin quiz! In just a few minutes, you'll share your skin concerns and upload a few photos for a licensed dermatology provider, who will create a custom treatment plan tailored to your unique goals. Restrictions apply. See website for full details and important safety information. *Disclaimer: Unless otherwise stated, all products reviewed are gratis media samples submitted for editorial consideration.* Hosts: Carlene Higgins and Jill Dunn Theme song, used with permission: Cherry Bomb by Saya Produced by Dear Media Studio See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
© 2020-2026 Ivy Podcast Discovery LLC
